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Abstract 
 RNA interference (RNAi) has been found to be an important biological strategy 
for gene silencing. This pathway can be used as a gene therapy approach by using 
synthetic short interfering RNA (siRNA) molecules to promote the silencing of 
undesirable target genes. However, the delivery of nucleic acids into the cells is a very 
inefficient process due to several extracellular and intracellular barriers. Several 
physical, chemical and biological strategies have been developed to promote the 
delivery of nucleic acids into cells. Although viral vectors have been reported to be the 
most efficient nucleic acid delivery systems, they trigger the immune system and 
promote high levels of toxicity.  
 Non-viral vectors, though not as efficient as their viral counterparts, appeared 
as a safer method for therapeutic gene delivery. In this field, cationic liposomes 
emerged as one of the most promising and widely used non-viral gene carriers. Recent 
studies from our group have established a novel liposomal formulation for siRNA 
delivery, based on the cationic lipid dioctadecyldimethylammonium bromide (DODAB) 
and the helper lipid monoolein (MO). This liposome formulation has promoted 
efficient gene silencing in a human non-small cell lung carcinoma cell line (H1299). 
 In this project, we aimed to improve the silencing efficiency of DODAB:MO (2:1) 
liposomes, by promoting the co-encapsulation of siRNA with additional anionic 
components. Poly-L-glutamic acid (PG1 or PG2) or non-coding plasmid DNA (pDNA) 
were added to siRNA suspension and encapsulated within DODAB:MO (2:1) liposomes. 
The systems obtained were compared with lipoplexes containing only siRNA. 
Lipoplexes were characterized in order to understand the differences caused by 
addition of the anionic components. The results obtained during this project suggest 
that the addition of either pDNA or PG molecules to siRNA/DODAB:MO lipoplexes 
results in systems with similar physicochemical properties, namely size and surface 
charge. Nevertheless, some improvements in the siRNA encapsulation efficiency, 
cellular internalization and cytotoxicity were obtained when compared to siRNA 
lipoplexes. Additionally, lipoplexes co-encapsulating siRNA and pDNA or PG have 
promoted higher EGFP gene silencing efficiency, suggesting that co-encapsulation of 
siRNA with an additional anionic cargo can improve silencing efficiency of our 
liposomal formulation. 
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Resumo 
 Desde a sua descoberta, o RNA de interferência (RNAi) tornou-se uma 
estratégia biológica importante para o silenciamento de genes. Esta via pode ser usada 
como uma abordagem de terapia genética, utilizando short interfering RNA (siRNA) 
para promover o silenciamento de genes indesejáveis. No entanto, a entrega de siRNA 
em células é um processo muito ineficiente devido a várias barreiras extracelulares e 
intracelulares. Várias estratégias físicas, químicas e biológicas têm sido desenvolvidas 
para promover a transferência de ácidos nucleicos para as células. Vários estudos 
mostram que, vetores virais são sistemas de entrega eficazes, contudo, desencadeiam 
resposta imunitária e promovem níveis elevados de toxicidade. 
 Os vetores não virais, embora não tão eficientes como os seus homólogos 
virais, aparecem como um método mais seguro para a entrega de siRNA. Neste campo, 
os lipossomas catiónicos tornaram-se num dos vetores não virais mais promissores e 
amplamente utilizados. Estudos recentes do nosso grupo estabeleceram uma nova 
formulação lipossomal para a entrega de siRNA, com base no lípido catiónico brometo 
de dioctadecildimetilamónio (DODAB) e o lípido adjuvante monooleína (MO). Esta 
formulação de lipossomas foi capaz de promover o silenciamento genético de forma 
eficiente numa linha celular humana de células não-pequenas de carcinoma pulmonar 
(H1299). 
 Neste projeto, procuramos melhorar a eficiência de silenciamento de liposomas 
DODAB:MO (2:1), através da promoção da co-encapsulação de siRNA com 
componentes aniónicos adicionais. Poli-glutamato (PG1 ou PG2) ou DNA plasmídico 
não codificante (pDNA) foram adicionados à suspensão de siRNA e encapsulados em 
liposomas DODAB:MO (2:1), e os sistemas obtidos foram comparados com lipoplexos 
contendo apenas siRNA. Os lipoplexos foram caracterizados de modo a compreender 
as diferenças causadas pela adição dos componentes aniónicos. Os resultados obtidos 
durante este projeto sugerem que a adição de moléculas de pDNA ou PG a lipoplexos 
compostos por siRNA e lipossomas DODAB:MO (2:1) resulta em sistemas com 
propriedades físico-químicas semelhantes, mais especificamente, o tamanho (Z-
average) e a carga superficial (ζ-potential). No entanto, foram obtidos algumas 
melhorias na eficiência de encapsulação de siRNA, internalização celular e 
citotoxicidade destes sistemas, quando comparado com lipoplexos com apenas siRNA. 
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Além disso, lipoplexos onde o siRNA é co-encapsulado com pDNA ou PG, promoveram 
maior eficiência de silenciamento do gene EGFP em linhas celulares 293T/GFP-puro, 
sugerindo que a co-encapsulação de siRNA com uma carga aniónica adicional pode 
melhorar a eficiência de silenciamento da nossa formulação lipossomal. 
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I - Introduction 
1. Gene Therapy 
 The concept of gene therapy, first proposed in 1972 by Friedmann and Roblin 
[1], can be defined as the attempt to correct genetic disorders by adding exogenous 
nucleic acids to the target cells, in order to enhance or repress the expression of 
specific nucleotide sequences [2], [3]. 
1.1 Gene Silencing therapy 
 Gene silencing is a type of gene therapy defined as the interruption, or 
suppression, of the expression of a gene at the transcriptional or translational levels. In 
the mid 80's a post-transcriptional method was reported and defined as antisense 
therapy. The antisense technology uses homologous RNA, DNA or chemically altered 
nucleic acid sequences that hybridize with target mRNA transcripts, inhibiting their 
expression. This technique finds its hurdle due to the high molecular weight of the 
antisense nucleic acids, which rises several problems in the delivery process of the 
therapeutic agents [4], [5].  
 In the early 90's, nucleic acid molecules with three-stranded, or triple-helical 
structure (triplex DNA) were used to directly target the transcriptional regulation of 
gene expression. Triplex formation occurs when DNA or RNA oligonucleotide binds to 
homopurine region of DNA, these triplex forming oligonucleotides can be used to block 
the transcription of specific genes, [4], [6]. However there are many obstacles to 
triplex DNA therapy, such as, low cellular uptake, complexity of triplex structures 
formation and difficulty to find long uninterrupted homopurine sequences to promote 
stable triplex binding [6]. In the late 90's a new gene silencing approach was 
discovered by Fire et al. [7]: the RNA interference (RNAi) mechanism. 
1.2 RNA interference mechanism 
 The RNA interference mechanism was first described in Caenorhabditis elegans 
in 1998 by Fire et al. [7], when the authors found that the introduction of RNA into 
cells could be used to interfere with the function of an endogenous gene. RNA (Fig.1) is 
a critical pathway naturally used by cells to control gene expression, and to provide 
protection against genetic damage induced by virus or mutations. In a simplified way, 
when a threat to the integrity of the genome occurs, a double-stranded RNA (dsRNA) is 
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broken into short pieces of 21 to 25 nucleotides, called short interfering RNA (siRNA), 
by the ribonuclease III enzime Dicer. This siRNA triggers the activation of an RNA-
induced silencing complex (RISC), that targets specifically the homologous messenger 
RNA (mRNA) for enzymatic degradation [4], [8]–[11]. The main components of the RISC 
complex are the Argonaute 2 proteins, responsible for mRNA degradation. The fact 
that siRNA molecules have perfect homology to the target mRNA sequences makes 
this mechanism specific and efficient, because, unlike antisense and triplex 
approaches, dsRNA activates a normal cellular process leading to a highly specific 
mRNA degradation. 
 
Figure 1 - Representative scheme of RNAi. Double stranded RNA (dsRNA) is processed into short interfering RNA 
(siRNA) by Dicer enzymes. siRNA molecules formed will attach to a multiprotein complexed known as RISC, which 
after activation will bind to target mRNA. mRNA is cleaved and degraded by cellular nucleases [12]. 
 
 The application of dsRNA longer than 30 nucleotides has been associated with 
the activation of interferon (IFN) response genes, and also to a non-specific inhibition 
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of protein synthesis, constraining the use of dsRNA in gene therapy [12]–[14]. Only in 
2001 a novel solution to this obstacle was found, when studies carried  out by Tuschl et 
al. [11] and Caplen et al. [15] described that successful gene silencing could be 
achieved by the delivery of siRNAs (21-22 bp long) into mammalian cells [12]–[14]. 
 Until now, two main strategies were tested using the RNAi pathway for genetic 
therapy purposes, based on either generation or administration of these short dsRNAs. 
The first approach is based on short hairpin RNAs (shRNAs), single-stranded molecules 
of 50–70 nucleotides in length, that form stem–loop structures [13]. It is an 
endogenous approach, since it allows the stable intracellular expression of shRNAs, 
which are then processed into active siRNAs by the host cell [13]. The control of siRNA 
levels and the inability to switch off the production of siRNAs are the main 
disadvantages of using shRNA. The second strategy consists in the exogenous 
application of synthetic siRNAs. As gene silencing induced by synthetic siRNA is limited 
by the number of RNA molecules present in the cell, the treatment can be stopped 
when it's no longer necessary. The use of siRNA for gene silencing has become the 
prime method for mammalian cell genetic analysis. This method presents potential for 
therapeutic treatment of a wide variety of diseases [16]. 
1.3 Molecular targets for gene silencing 
 Several therapeutic treatments using the RNA interference pathway have been 
developed, these treatments have different molecular targets. Targets important for 
gene therapy in cancer are mainly tumour suppressor genes, cell-cycle modulators, 
and growth factors [17]. Table 1 presents some of the targeted genes for a variety of 
cancer treatments in animal models [18].  
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Table 1 - List of common target genes of gene silencing for cancer therapy in a variety of animal models [18]. 
Animal Models Targeted Genes 
Liver metastasis mouse model Bcl-2 
Prostate cancer xenograft Raf-1; CD31; Bcl-2 
Gastric cancer xenograft VEGF 
Breast cancer xenograft  c-raf; Her-2; RhoA 
Ovarian cancer xenograft EphA2; FAK; ADRB2; IL-8 
Lung cancer xenograft EGFR 
Orthotopic glioblastoma PTN 
 
1.3.1 Epidermal Growth Factor Receptor (EGFR) 
 One recognized target for gene silencing is the epidermal growth factor 
receptor (EGFR). This 170-kd glycoprotein consists in an extracellular binding domain, a 
transmembrane lipophilic region, and an intracellular domain with tyrosine kinase 
activity. After the binding of a ligand, such as the epidermal growth factor (EGF) or 
transforming growth factor (TGF-α), EG R d me  ze  and, act vate  the  nt  n  c p ote n 
tyrosine kinase, leading to a cascade of downstream signalling events that influence 
the behaviour of epithelial cells and tumours of epithelial cell origin [19], [20]. EGFR is 
overexpressed in many tumours (colorectal, head and neck, lung, ovarian, breast and 
renal cancer), and its signalling pathway is involved in cell differentiation, proliferation, 
migration, development of angiogenesis, and apoptosis inhibition [19], [21]. EGFR is a 
good target for cancer therapy since it has proven to be involved in the initiation, 
growth and metastasis of many human tumours. The main strategies for targeting 
EGFR are based on monoclonal antibodies directed against the extracellular receptor 
domain, which interferes with ligand binding, small-molecule compounds that target 
intracellular domain, inhibiting the activation of the tyrosine kinase activity and siRNA 
molecules which interfere with production of the EGFR protein at the mRNA level [19]. 
Gene silencing therapeutic approach has been reported to successfully reduce EGFR 
expression using a variety of vectors to transport siRNA into tumour cells, which makes 
this approach extremely promising [17], [21]–[23]. 
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2. Vectors for Gene therapy 
 A successful gene therapy approach depends on the efficient delivery of nucleic 
acid molecules into cells. Actually, this represents the main problem in gene therapy, 
since the application of naked nucleic acid molecules is very inefficient due to several 
obstacles in the delivery process. Due to their small size, naked siRNAs are eliminated 
by kidney filtration, resulting in a short half-life when applied in vivo. Also, the nucleic 
acid molecules are prone to degradation due to the presence of nucleases in biological 
fluids and cells [24]. Moreover, nucleic acids are negatively charged due to the 
phosphodiester present in their backbone, which creates an electrostatic repulsion 
between nucleic acid molecules and the anionic headgroups of cell membrane 
phospholipids. This electrostatic repulsion hinders the passive diffusion of nucleic acids 
into the cells [12]. Therefore, high amounts of naked siRNA are required in order to 
achieve in vivo efficient silencing. Nevertheless, an elevated dose of siRNA is 
associated with non-specific effects on non-targeted genes, triggering immune 
responses and anti-angiogenic effects independent of the siRNA sequence [16]. 
 In order to overcome the limitations in the nucleic acid delivery process and to 
enhance the transfection efficiency, a wide variety of physical and chemical methods 
have been developed. The use of delivery systems has commonly two main 
approaches: biological (viral vectors) and chemical (cationic lipids or polymers). The 
biological approach has been the most common approach, and is based on the use of 
viral vectors [25], while the chemical approach is based on the use of synthetic non-
viral vectors [26]. 
2.1 Viral vectors versus non-viral vectors 
 Viruses are highly evolved organisms that have developed a very efficient 
mechanism to internalize their genome into host cells and exploit cellular machinery to 
facilitate replication [27]. By erasing part or the whole viral coding region, as well as 
promoting the insertion of siRNA or pDNA into the virus capsid, viruses can be used as 
vectors for gene therapy. Although the use of viral vectors results in relatively high 
transfection efficiencies, several drawbacks are associated with this method. A limited 
loading capacity, the complexity of vector production, and particularly the safety 
concerns such as the possibility of immunogenic/inflammatory responses and risk of 
mutations, are important disadvantages associated with this treatment [28], [29]. 
6 
 
Actually, clinical trials using viral vectors have already caused the death of a patient 
when, in 1999, the injection of an adenovirus vector induced systemic inflammatory 
response syndrome that resulted in intravascular coagulation, acute respiratory 
disorder and multi organ failure [27]. 
 Non-viral vectors were developed to overcome the safety concerns associated 
with viral vectors. Non-viral vectors are normally composed of synthetic  cationic lipids 
(lipoplexes) or polymers (polyplexes)[30], although dendrimers[31], chitosan[32], and 
peptides[33] have also been studied for the delivery of nucleic acids. Unlike viral 
vectors, these carriers do not trigger specific recognition by the immune system, 
resulting in lower chance of immune responses. Also they have the potential to 
transport larger genetic cargos, are much easier to assemble, and may be tuned to 
enhance specificity [34], [35]. However, the transfection efficiency of non-viral vectors 
is still relatively low when compared to viral vectors, which is caused by the inability of 
the vector to surpass the cellular barriers to deliver the genetic cargo. 
2.2. Barriers faced by non-viral vectors in gene delivery 
 In order to obtain successful in vivo delivery of nucleic acids using a non-viral 
vector, it must be able to overcome a variety of extracellular and intracellular barriers 
(Fig.2). 
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Figure 2 -Extracellular and intracellular barriers to gene therapy. Non-viral vectors such as liposomes were 
developed to deliver a variety of nucleic acids such as DNA, mRNA, short interfering RNA (siRNA) or microRNA 
(mRNA) to cells. For efficient delivery, non-viral vectors must be able to overcome extracellular and intracellular 
barriers. Extracellularly, vectors must be able to prevent degradation of the genetic cargo by serum endonucleases, 
avoid immune detection, nonspecific interactions and renal clearance from the blood. The vector used must also be 
able to promote cell entry in target tissues and subsequent endosomal escape. After endosomal escape, DNA must 
be transported into the nucleus, siRNA and miRNA must bind to the RNA-induced silencing complex (RISC) and 
miRNA must bind to translational machinery [35]. 
  
2.2.1 Extracellular Barriers 
 As mentioned before, the half-life of nucleic acids in physiological fluids and 
extracellular space is very short, so the vector selected must be able to protect its 
cargo in order to improve circulation time. In order to overcome these problems, the 
vector chosen needs to have colloidal stability, and reduced interaction with blood 
components such as proteins and cells, which may promote cargo release and particle 
aggregation. Protein binding can also trigger immune detection, leading to the 
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clearance of the vector by circulating macrophages before reaching the desired tissues. 
After evading immune detection and renal clearance the vector needs to extravasate 
from the bloodstream to the desired tissues and reach the target cells [35]. 
2.2.2 Intracellular Trafficking 
 After the vector reaches the desired tissues several obstacles arise, and the 
ability to promote efficient entry into the cell and induce endosomal escape are critical 
steps to obtain high transfection efficiencies. The cellular internalization process of 
non-viral vectors is not yet completely understood, since some studies have shown 
that the cellular uptake occurs mainly by endocytosis, but others have demonstrated 
that internalization by fusion with the plasmatic membrane can also occur for certain 
vectors such as liposomes [29]. The internalization efficiency of the vector is 
dependent on its size and hydrophilic nature. After cell uptake, the internalized 
particles become entrapped in the intracellular vesicles (endosomes) that fuse with 
lysosomes, where particle degradation occurs. Therefore, endosomal escape is an 
essential step for efficient delivery of the genetic cargo, as well as its dissociation from 
the vector after endosomal escape [2], [35], [36]. Cationic lipid based vectors (cationic 
liposomes) may fuse with endosomal membranes, facilitating endosomal escape and 
cargo release [35]. After dissociation from the vector, DNA molecules have to be 
further transported to the nucleus and RNA molecules must bind to Argonaute2 (aug2) 
protein, to form the RNA induced silencing complex (RISC) (siRNA and miRNA), or to 
the translational machinery (mRNA) [2], [35]. 
2.3. Liposomes as non-viral vectors 
 In 1965 Alec Bangham [37] first reported that, when in aqueous system, 
phospholipids self-assemble into closed bilayer structures forming lipid vesicles. Lipids 
are amphiphilic molecules, which means they are composed by a hydrophilic polar 
head group and hydrophobic tails. When in aqueous solution, lipids tend to organize in 
order to reduce entropically unfavourable interactions between the hydrophobic acyl 
chains and surrounding aqueous medium. The entropically favourable structure is 
obtained when the bilayer membrane formed by the lipids curves on itself, forming a 
closed vesicle, where the hydrophilic headgroups tend to face the aqueous phase [38]. 
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 The bilayer structure of liposomes is relatively easy to manipulate and can be 
formed in a diverse range of morphologies. Vesicle size and number of bilayers are 
important parameters to determine the ability of liposomes to encapsulate 
pharmaceutical compounds and their half-life time in circulation [39]. The most 
common morphologies of the vesicles are unilamellar, multilamellar and 
multivesicular, depending on the preparation methodology (Fig. 3).  
 
 
Figure 3 - Common vesicle size and lamellarity. Small unilamellar vesicles (SUV), large unilamellar vesicles (LUV), 
giant unilamellar vesicles (GUV), Multilamellar vesicles (MLV) and multivesicular vesicles (MVV). 
  Unilamellar vesicles are composed by a single bilayer membrane and present 
different size diameters. The size of small unilamellar vesicles (SUVs) ranges from 20 to 
100 nm, while large unilamellar vesicles (LUVs) can vary from 100 nm to 1 µm. For 
sizes bigger than 1 µm, liposomes are described as giant unilamellar vesicles (GUVs). 
Multilamellar vesicles (MLVs) are formed by multiple concentric bilayers and have a 
diameter that can vary from 500 nm to over 1 µm.  Multivesicular vesicles (MVVs) 
present roughly the same diameter of MLVs, but are formed by several smaller 
unilamellar vesicles inside a wider one [38]–[40]. Since larger liposomes are rapidly 
removed from blood circulation, smaller vesicle diameter are more favourable for drug 
or acid nucleic delivery [41]. Therefore, different methods for liposome preparation 
were developed in order to shape the lipid vesicles, and each method will produce 
different types of liposomes. The most common methods are lipid film hydration, 
ethanol injection, sonication and extrusion. 
 In addition to the size and number of lamellae, different liquid-crystalline lipid 
phases may exist, depending on the lipid molecules used in the system. The type of 
structure can be predicted by the packing parameter (P) of the lipid. The packing 
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parameter is the ratio between the area occupied by the hydrophobic region and the 
area occupied by the hydrophilic region, as defined by Equation 1. 
  
 
    
 Equation (1) 
 where (v) is the volume of the hydrocarbon, (a) is the effective area of the head 
group, and (lc) is the length of the lipid tail. As depicted in Fig. 4, different packing 
parameter values will lead to different lipid structures: lipids with P < 1/3 tend to form 
 phe  cal m celle ; l p d  w th 1/3 ≤   < 1/   o m cyl nd  cal m celle ; l p d  w th 1/  ≤   
< 1 form flexible bilayers or vesicles; when P=1 planar bilayers are formed; and when P 
> 1 inverted micelles are formed. When P exceeds 1, the area occupied by the 
hydrocarbon chains is much larger than the area of the head group, and the lipid tends 
to adopt a bilayer destabilizing structure called inverted micelle or inverted hexagonal 
phase. These structures seem to improve the transfection efficiency of liposomes [38], 
[42]. The lipid phase behaviour can also be modulated by changes in several 
parameters such as hydration, state of ionization (pH and ionic strength) and 
temperature [41]. 
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Figure 4 Liposome structures assumed by lipids according to their packing parameter. Lipid structure, 
when in an aqueous medium, is greatly influenced by the lipid packing parameter. Structures such as 
spherical micelles, flexible bilayers, vesicles, planar bilayers and inverted micelles can be obtained 
depending on the ration between hidrophobic and hidrophilic area [38]. 
 
2.3.1 Cationic Liposomes 
Cationic liposomes are spherical-shaped colloidal structures, formed by the self-
assembly of cationic lipid molecules in aqueous solution, composed by one or more 
concentric lipidic bilayers entrapping an aqueous compartment [39]. Liposomes 
present several interesting properties such as biocompatibility, biodegradability as well 
as the ability to entrap and protect either water-insoluble (hidrophobic) 
pharmaceutical agents into the hydrocarbon chain core of the bilayer, or water soluble 
molecules (hydrophilic) in the internal water compartment [40]. Due to these 
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attractive characteristics, cationic liposomes have been extensively studied as non-viral 
vectors for medical applications and for several other fields such as chemical and 
biochemical analytics, diagnostics, cosmetics, long lasting immune contraception, food 
and chemical industry [38], [39].  
In the late 80's a study developed by Felgner and colleagues [43] reported, for the first 
time, the ability of cationic liposomes to efficiently form complexes with DNA and 
transfect the COS-7 cell line. This study helped to understand the potential of 
liposomes for gene therapy. Since then several cationic lipids have been used to 
deliver nucleic acids to the cells [38], [44] (Fig. 5) 
 
Figure 5 Cationic lipids used in gene therapy. (A) representative structures of glycerol based cationic lipids; (B) 
cationic lipids not based on glycerol; (C) cholesterol-based cationic lipids. 
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2.3.2. Optimization of the liposome structure/composition 
 The use of cationic liposomes for delivery of nucleic acids present some 
drawbacks, such as fast elimination from blood [40], some cytotoxicity due to their 
positive charge, and the fact that they may also trigger non-specific interactions with 
cell components, serum proteins and enzymes [2]. In order to overcome these 
obstacles, several modifications can be done to improve their properties. The size, 
charge and surface characteristics of liposomes can easily be altered through the 
inclusion of specific compounds (helper lipids, stimuli-sensitive lipids) in the liposome 
formulation, or by surface modification.  
 Different cationic lipid mixtures can be prepared in order to obtain the most 
favourable structure for gene transfection. For instance helper or neutral lipids, such as 
dioleoylphosphatidylethanolamine (DOPE), dioleoylphosphatidylcholine (DOPC), 
cholesterol (CHO) and monoolein (MO), are often included in the formulation to 
improve the characteristics of liposomes. These lipids have the ability to convert the 
liposome lamellar phase into a non-lamellar phase [42].  The structural organization 
induced by this lipids is able to promote fusion with endosomal membranes and 
destabilization of lipoplexes during transfection. Several studies have shown that the 
presence of a helper lipid improved the transfection efficiency of the liposomes when 
compared to the cationic lipids alone, as well as decreased the cytotoxicity associated 
with the high positive charge of the liposomes [38], [45]–[47]. 
 One of the limitations for in vivo application of liposomes as non-viral vectors is 
their circulation half-life, which decreases the possibility of liposomes to reach their 
site of action. The optimization of liposomes as non-viral vectors has been made not 
only by changing the liposome composition, but also by the inclusion of molecules at 
the liposomes surface. A common method to obtain liposomes with increased half-life 
involves its surface modification with inert and biocompatible polymers, such as 
polyethylene glycol (PEG). PEG can be used to coat the liposome surface, reducing the 
peripheral liposome charge, and therefore the binding of proteins. As a consequence, 
the liposome recognition by opsonins decreases, avoiding liposome clearance, 
increasing circulation time and reducing toxicity [40], [48]. The specificity of liposomes 
can also be improved by adding molecules such as folate or immunoglobulins, that will 
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be covalently coupled to the liposome surface and will allow the targeting to specific 
cells [41].  
2.3.3 Formation of cationic lipoplexes 
 Cationic liposomes can be used as non-viral vectors for gene therapy due to 
their ability to easily promote complexation with nucleic acids, forming lipoplexes that 
are capable of transporting these nucleic acids into cells. The electrostatic interaction 
between negatively charged phosphate groups of the nucleic acid molecules, and the 
positively charged liposomes, drives the spontaneous formation of lipoplexes [49]. This 
interaction will lead to nucleic acid charge neutralization, followed by a disruption of 
liposomes and intermediate condensation of nucleic acid molecules into lipoplexes. 
Finally, relaxation and rearrangement into a more ordered states occurs [50]. Efficient 
complexation is dependent on the charge ratio (CR+/-), which is the ratio between 
positive charges from liposomes and negative charges from nucleic acids. In order to 
completely neutralize the negative charges, an excess of cationic lipid is added to the 
nucleic acids, resulting in positively charged lipoplexes that promote electrostatic 
interactions with cell membrane.  Since siRNA are much smaller than pDNA molecules, 
the siRNA and pDNA complexation process presents some differences, and siRNA 
nanocarriers require less negative charges and form smaller sized nanoparticles. 
However, siRNA lipoplexes are less stable than pDNA lipoplexes, as pDNA promotes a 
stronger polycation-mediated electrostatic collapse into small compact particles [51]. 
Due to their different characteristics, siRNA and pDNA transfection mechanisms will be 
significantly different [52].  
2.4. The system DODAB:MO for nucleic acid delivery 
 In recent years a novel liposome formulation for nucleic acid delivery was 
proposed, based on the helper lipid monoolein (MO) and cationic lipids from 
dioctadecyldimethyl family (DODAX) [45], [49], [53]–[59]. Liposomes composed by 
DODAB/DODAC and MO were extensively studied as pDNA and siRNA carriers, and 
have proved to be a very promising transfection agent. 
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2.4.1 DODAB 
 The long-chained cationic surfactant dioctadecyldimethylammonium bromide 
(DODAB) is a synthetic lipid that tends to assemble into closed bilayers. DODAB 
resembles membrane phospholipids since it is composed by two saturated alkyl chains 
linked to hydrophilic group [60] (Fig. 7A). In an aqueous medium and above the phase 
transition temperature (Tm= 45 ˚C) [58], [61], [62], DODAB tends to form large  
unilamellar vesicles [49], [53]. This lipid presents a small critical vesicle concentration 
(CVC), which allows the formation of vesicles at very low concentrations [45]. When 
applied in vivo, DODAB presents strong rigid lamellar phase due to its elevated Tm that 
becomes a limiting step for gene delivery since rigid structures do not favour 
membrane fusion. Therefore, the combination with other lipids has been tested to 
improve the transfection efficiency of DODAB-based liposomes [58], [61], [62]. 
2.4.2 Monoolein (MO)  
 1-monooleoyl-rac-glycerol (MO) is an amphiphilic neutral lipid of natural origin, 
composed of a single hydrocarbon chain, attached to a glycerol backbone by an ester 
bond (Fig. 6B). The remaining two hydroxyl groups of the glycerol moiety confer polar 
characteristics to the polar head of the molecule [63]. A concise summary of phase 
propensity at different temperatures and water content has been established for MO 
(Fig.6). This phase diagram shows that, even in excess of water, MO presents two 
inverted bicontinuous cubic phases, this liquid crystalline phases consisting in a pair of 
interpenetrating, but non contacting, aqueous channels, separated by a single 
continuous lipid bilayer [64].  
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Figure 6 -  Temperature-composition phase diagram of monoolein. In small amounts of water monoolein can form 
a lamellar crystalline phase (Lc) or a similar fluid isotropic phase (FI) depending on the temperature. As the amount 
of water is increased, a l qu d c y tall ne (Lα), and two inverted bicontinuous cubic phases (la3d,Pn3m) are adopted. 
Schematic representations of the various phases is included, in which colored zones represent water [65]. 
 
 The phase behaviour of MO presents interesting characteristics. The ability to 
form non-lamellar phases has been explored in many different fields such as 
pharmaceutics, cosmetics, agriculture, protein crystallization and drug delivery [63]. 
Furthermore, due to the richness of MO phase diagram, the addition of this neutral 
lipid has been proposed in the development of lipoplexes for gene transfection [49].  
 
Figure 7 - Molecular structure of DODAB and MO. A - molecular structure of DODAB, B- molecular structure of MO  
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2.4.3 The mixture DODAB:MO 
 Nucleic acid complexation with DODAB:MO liposomes has been intensively 
studied during the past few years [49], [54]–[58] . It was demonstrated that the 
addition of MO to lipid mixture has a strong influence in liposome/lipoplex 
morphology and consequent transfection efficiency performance.  
The liposomal mixed system composed by MO and DODAB was studied by phase 
scanning imaging in order to characterize the phase behaviour and aggregate 
morphology of DODAB:MO liposomes at different molar ratios and temperatures. This 
study showed that the morphology obtained is strongly dependent on DODAB/MO 
molar ratio. When the liposomal formulation is of equimolar composition, or when 
DODAB is in excess, the structures assembled are mostly bilayers; whereas 
formulations presenting higher amount of MO tend to promote densely packed cubic 
oriented particles (Fig.8). Additionally, it was found that increasing the temperature of 
the formulations has a similar influence on the vesicles morphology as the increase of 
MO concentration [53]. 
 
Figure 8 Phase scanning imaging of different DODAB:MO mixtures                   C. Lα is the lamellar liquid 
crystalline phase, L the isotropic phase, cub the isotropic cubic phase and cr, hydrated crystals [53] 
 The addition of a helper lipid such as MO to DODAB, that presents a very low 
Tm, can effectively lower the Tm of the final lipid mixture. This has implications on the 
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liposomal membrane fluidity and lipid organization, which are important parameters 
influencing nucleic acid encapsulation efficiency and transfection efficiency of the 
lipoplexes [54]. Additionally, studies regarding the nucleic acids complexation 
efficiency of DODAB:MO showed that the MO tendency to form inverted non-lamellar 
structures promotes inter-lamellar attachments (ILAs) and packing defects, resulting in 
fluidization/destabilization of the lamellar arrangement of DODAB. These structures 
help in the release of nucleic acids from the lipoplex by membrane fusion, enhancing 
transfection efficiency [53], [57]. The fluidization promoted by the presence of MO also 
leads to a high encapsulation efficiency improving lipoplex resistance to biological 
conditions [29], [45], [49].  
 Transfection efficiency studies with DODAB:MO at different molar ratios were 
performed both for siRNA [54] and pDNA [55]–[58]. In both cases, lipoplexes with less 
MO presented better transfection efficiencies when compared with lipoplexes with 
higher MO contents. These results show that the use of MO as a helper lipid may be 
finely tuneable in order to improve lipoplexes transfection [66].  
2.4.4 Optimization of DODAB:MO for siRNA delivery: inclusion of anionic cargo  
 pDNA and siRNA molecules present substantial chemical and structural 
differences, such as molecular weight and molecular topography. These differences 
may lead to different complex formation when interacting with cationic lipids. Since 
different complexes are obtained, it is presumable that cell interaction, uptake and 
distribution will vary, resulting in different intracellular pathways. These differences 
will have a strong impact on the effectiveness of the gene delivery system.  
 Recent studies using different liposomal formulations and different cell lines 
have demonstrated that the addition of non-coding pDNA molecule to siRNA prior to 
complexation with liposomes results in lipoplexes with enhanced silencing efficiency 
both in vitro [9], [16] and in vivo [67], [68]. Similar results have been reported for 
simultaneous complexation of pDNA and non-coding pDNA in polyplexes [3]. The 
mechanism behind this effect is still not entirely understood. 
 Furthermore, no major difference between siRNA lipoplexes, DNA lipoplexes 
and siRNA/pDNA lipoplexes structures were detected [16]. Also, the administration of 
these lipoplexes did not translate into significant differences in the amount of 
transferred siRNA [9]. The differences observed, were associated with the lower 
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surface of the lipoplexes  formed due to  the less amount of cationic lipid necessary to 
efficiently encapsulate siRNA combined with pDNA. This is a benefit, because 
decreasing  the amount of lipid,  leads to a lower cytotoxic response and less off-target 
effects triggered by these lipoplexes [16]. Nevertheless, even though no relevant 
structural changes were detected, the confocal microscopy studies performed were 
able to confirm that the internalization pathways may differ for siRNA/pDNA 
lipoplexes, siRNA lipoplexes and pDNA lipoplexes, since the cellular localization was 
different for each lipoplex formulation [9]. It is important to realise that, even in a 
eukaryotic non-coding version, pDNA is not an inert molecule, and it might still lead to 
the undesirable expression of molecules. Moreover, studies have shown that when 
applied in high doses to culture cells, pDNA containing siRNA lipoplexes can be highly 
toxic [10]. Therefore, several anionic polymers have been studied to replace pDNA as 
the anionic cargo for simultaneous complexation with siRNA, and improve this way the 
safety profile of the system by reducing immunogenicity [10].  
 Addition of poly-glutamate to siRNA prior to lipoplex formation instead of 
pDNA has been recently reported [10], [69], [70]. Poly(L-glutamic acid) (PG) is a 
biodegradable, non-toxic synthetic polymer, composed by naturally occurring l-
glutamic acid molecules linked together through amide bonds. The free y-carboxyl 
group in each unit of l-glutamic acid is negatively charged at a neutral pH, and enables 
drug attachment. PG is widely applied in the fields of drug delivery, tissue engineering, 
and biomedical materials [71], [72].  
 Reports have shown that the inclusion of this polymer instead of pDNA also 
lead to the formation of lipoplexes with colloidal stability and improved gene silencing 
efficiency [70]. When siRNA/pDNA/cationic lipid and PG/pDNA/cationic lipid 
complexes where compared, lipoplexes containing pDNA promoted higher transfection 
efficiency than lipoplexes containing PG. However, a high cytotoxicity was also 
associated with the first systems. The substitution of pDNA by PG has lead to a 
significant decrease in cellular toxicity at higher siRNA doses, while maintaining some 
improvement in gene silencing efficiency. Thus, the addition of polymers such as poly-
glutamate appears to have better potential than plasmid DNA for the development of 
a safe and effective siRNA delivery system [10], [69]. 
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3. Objective 
 Since the discovery of RNAi as a valuable tool for gene therapy, a lot of effort 
has been put into developing suitable carriers for siRNA delivery into cells, as naked 
therapeutic siRNA molecules show very poor biodistribution and pharmacokinetics in 
the body. The use of vectors based on cationic liposomes emerged as a promising 
delivery method, due to their relatively high transfection efficiency and low toxicity 
and immunogenicity, compared to their viral counterparts. A variety of modifications 
can still be made in liposomes structure in order to enhance their transfection 
efficiency. 
 In recent studies, our group has developed DODAB:MO liposome formulations 
capable of effectively encapsulate and deliver siRNA into cells, resulting in relatively 
high silencing efficiency. The main objective of this thesis was to develop and 
characterize novel systems for therapeutic siRNA delivery based on the addition of 
anionic cargo (pDNA or PG) to the previously tested DODAB:MO (2:1)/siRNA 
lipoplexes. The aim is to study the differences in encapsulation, cellular uptake, 
cytotoxicity and silencing efficiency between the previously established system and the 
newly developed formulations. Moreover, the differences between the anionic cargo 
(pDNA, PG with low mol. wt. and PG with high mol. wt.) were to be assessed, to 
understand which one would be more suitable for co-encapsulation with siRNA. 
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II - Materials and Methods 
i - Materials 
 Dioctadecyldimethylammonium bromide (DODAB) was purchased from Tokyo 
Kasei (Tokyo, Japan). 1-monooleoyl-rac-glycerol (MO), Poly-L-glutamic acid sodium salt 
(PG) (3000-15000 and 15000-50000 mol wt), 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), Thiazolyl Blue Tetrazolium Bromide (MTT), Dimethyl 
sulfoxide solution (DMSO), GenEluteTM Plasmid Miniprep Kit, Puromycin 
dihydrochloride and Hoechst Stain solution were obtained from Sigma-Aldrich (St. 
Louis (Mo.), USA). 293T and MDA-MB-468 cell lines were purchased from American 
Type Culture Collection (ATCC) (Manassas (Va.), USA) and 293T/GFP-puro cell line from 
Cell Biolabs (San Diego (CA), USA). Dulbecco's modified Eagle's Medium (DMEM), Fetal 
Bovine Serum (FBS), L-glutamine, Penicillin/Streptomycin and Trypsine-EDTA were 
purchased from Biochrom (Berlin, Germany). The  Sc  pt™ Reve  e T an c  pt on 
Supe m    o  q  R and the  Taq™ Un ve  al SY R® Green Supermix kits were obtained 
from BIO-RAD (Hercules (CA), USA). SV Total RNA Isolation System kit was obtained 
from Promega (Madison (WS), USA), Quant- T™ R boG een® RN     ay K t and 
Lipofectamine® RNAiMAX Transfection Reagent from Life Technologies (Eugene (OR), 
USA) and Hank's Balanced Salt Solution (HBSS) from Lonza (Basel, Switzerland). 
Absolute ethanol was purchased from Merck Milipore (Berlin, Germany), 1,2-dioleoyl-
sn-glycero-3-phosphatidylethanolamine-7-nitrobenzofurazan (NBD- E) (λe c = 46  nm; 
λem =  3  nm)   om  vant   ola  L p d  ( laba te ,  L, US ), and pGL4.20 plasmid DNA 
was kindly given by Cristina Carvalho, Ph.D. student. siRNA targeting the enhanced 
green fluorescent protein (siEGFP) (5'CAAGCUGACCCUGAAGUUdTdT3'), a siRNA 
negative control (sicontrol) (5'UGCGCUACGAUCGACGAUdTdT3'), siRNA targeting the 
EGFR protein (siEGFR) (5'UGAGCUUGUUACUCGUGC3') and a scrambled anti-BCR-ABL 
sequence (siSCRAMB) ( ′GU U   GUUUU GGG  GdTdT3′) were purchased from 
Integrated DNA Technologies (Iowa, USA). The siRNA were diluted in DEPC-treated 
water and stored at -20 °C until used. 
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ii - Methods 
1. Preparation of DODAB:MO liposomes 
 Stock solutions of dioctadecyldimethylammonium bromide (DODAB) and 1-
monooleoyl-rac-glycerol (MO) were prepared in ethanol, at 20 mM. The liposome 
formulation was prepared by mixing the appropriate volume of DODAB and MO in 
order to obtain a molar ratio of 2:1 (mol:mol), after which one of the methods 
described below was performed to obtain the liposomes. 
1.1 Methods for liposome preparation 
 Various methods for the preparation of liposomes were tested, and the 
produced liposome suspension evaluated by Dynamic Light Scattering (DLS) in order to 
understand which method produced liposomes with more suitable characteristics for 
transfection in mammalian cells. Sonication, extrusion and ethanol injection methods 
where used to shape the liposomes.  
1.1.1 Sonication 
 Sonication is a commonly used method for the preparation of liposomes. The 
acoustic sound produced by the sonicator induces pressure on lipid suspensions, 
breaking up the larger, multilamellar vesicles into smaller ones, that may be 
unilamellar or multilamellar [73]. The size of the particle can be shaped by controlling 
the time of exposure, as well as the amplitude (A) applied. This method has the 
advantage of being less time-consuming than other methods, but the liposome size 
obtained after sonication are not as reproducible as in methods like extrusion [74]. 
 For the preparation of DODAB:MO (2:1) by the sonication method, appropriate 
volumes of DODAB and MO were added to 5 mL of HEPES buffer (25 mM, pH 7.4), to 
form liposomes at a concentration of 3 mM. Afterwards, the liposome formulation was 
subjected to sonication in a Qsonica Misomix S-4000 Sonicator, with the ultrasonic 
frequency fixed at 20 kHz. Sonication was performed by ultrasonic bath at different 
amplitudes (60, 70, 80 and 90 % A) and time of exposure (5,10 and 20 min).  
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1.1.2 Extrusion 
 Extrusion is one of the most common methods used for controlling the size of 
liposome suspensions. The lipid suspension is forced through a polycarbonate 
membrane with a well defined pore size, resulting in monodisperse unilamellar 
liposomes with diameter similar to the pore size [75]. The primary advantages of this 
method are the formation of a monodisperse population of liposomes and 
reproducibility [74]. The retention of lipid by the membrane filter is the main 
disadvantage, as well as the time consumed in the process. 
 For the preparation of liposomes by extrusion, suitable amounts of DODAB and 
MO (20 µM stock solution in ethanol) were added to a round bottom flask, together 
with 3 mL of ethanol, to obtain a homogeneous film. The solvent was then evaporated 
in a rotary evaporator at 60 ˚C, under vacuum, for 15 min. After evaporation, the lipid 
film formed was hydrated with 5 mL HEPES buffer (25 mM, pH7.4). The rotation 
process was maintained for 15 min at 60 ˚C, and a 3 mM suspension of DODAB MO 
(2:1) liposomes was obtained. After the lipid film hydration, the liposome preparation 
was subject to a process of extrusion, in order to obtain liposomes with acceptable size 
characteristics. Using a Northern Lipids Lipex Extruder with polycarbonate filters 
(Whatman, USA), the liposome preparation was forced to pass through a 400 nm pore 
sized filter once, and four times through a 100 nm pore sized filter. The process was 
conducted at 60 ˚C, the temperature above the phase transition temperature of the 
lipids, which facilitates the passage through the filters and diminishes the lipid 
retention. 
1.1.3 Ethanol Injection  
 Ethanol injection is a fast and simple process for the preparation of liposomes. 
The process is based on the injection of an ethanol solution of lipids, with a thin needle 
or pipette tip, into an aqueous solution, while stirring. The lipids instantaneously self-
assemble into liposomes. The size and shape of the liposomes depend on several 
parameters and can be tuned to form the more suitable liposomes for a certain 
application. Parameters such as temperature, type of lipid, lipid concentration, type of 
buffer, and even the stirring speed, can greatly influence the size and shape of the 
produced liposomes. This method has the disadvantage of producing more 
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polydisperse liposome suspensions, as well as less reproducible results than the 
extrusion method [76][77]. 
 For the production of DODAB:MO (2:1) liposomes by the ethanol injection 
method, DODAB and MO were mixed at the appropriate ratio, and immersed into a 
bath above the lipid transition phase temperature (60 ˚C). The lipids were then quickly 
pipetted drop by drop into 2.5 mL HEPES buffer (25 mM, pH 7.4), under strong vortex 
for 15 s, alternating with 25 s in the a water bath at 60 °C, in order to maintain the 
temperature. During the process, the organic solvent evaporates due to the high 
temperature, resulting in an aqueous solution of DODAB:MO (2:1) with a final 
concentration of 3 mM.  
2. Plasmid DNA 
2.1 pGL4.20 
 The pGL4.20 [luc2/Puro] vector represented in Fig. 9 is responsible for the 
encoding of luciferase reporter gene luc2 (Photinus pyralis), a synthetic reporter gene, 
which has been codon optimized for mammalian expression. It also contains a 
mammalian selectable marker for puromycin resistance. Since this vector does not 
contain a promoter, it contains multiple cloning regions to allow the cloning of a 
promoter. Thus, it can be used as a non-coding plasmid DNA (pDNA), which makes it 
suitable for this work. 
 
Figure 9 - Schematic representation of pGL4.20 [luc2/Puro] vector 
 
25 
 
2.2 Transformation of competent cells  
  Escherichia coli Xl1-Blue competent cells were transformed by the heat shock 
transformation method [78]. Briefly, a sample of the plasmid pGL4.20 was added to 
200 µL competent cells, which were then kept on ice for 30 min. Afterwards, the cells 
were put in a water bath at 42 ˚C for 30 seconds and then transferred to ice for 10 min. 
This variation of temperature leads to a heat shock that will enhance the membrane 
permeability of the competent cells, allowing a more efficient internalization of the 
plasmid. 800 µL of SOC Medium (2 % tryptone peptone, 0.5 % yeast extract, 2.5 mM 
KCl, 10 mM NaCl , 10 mM MgSO4, 10 mM MgCl2, 20 mM glucose) were then added to 
the cells, which were incubated for 1 h  one hour at 37 ˚C and 200 rpm. After 
incubation, the cells were centrifuged at maximum rotation per minute for a few 
seconds. The pellet obtained was re-suspended in 50 µL supernatant and then spread 
in a petri dish with LB Medium (1 % tryptone peptone, 0.5 % yeast extract, 1 % NaCl, 2 
% agar) with 100 µg/µL ampicillin. The petri dish was left for incubation overnight at 37 
˚C, along with a petri dish with the same competent cells without the transformation 
process, as a control. The resistance acquired by the transformed cells allowed them to 
form colonies, while the non-transformed cells showed no formation of colonies due 
to their susceptibility to ampicillin. One of the colonies was then selected and 
transferred into approximately 200 mL LB medium, and grown overnight at 37 ˚C and 
200 rpm. 
2.3 Purification of plasmid DNA  
 After the amplification of the plasmid DNA (pDNA) by the transformed bacterial 
cells, the plasmid must be isolated. The isolation and purification was made using the 
GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich, USA), according to the 
manu actu e ’  p otocol. The isolated pDNA was re-suspended in ultra-pure water and 
analysed in the NanoDrop ND 1000 Spectrophotometer, to determine the nucleic acids 
concentration and confirm the purity of the sample, by measuring the absorbance 
ratio at 260/280 nm. 
 
26 
 
3. Preparation of DODAB:MO (2:1) lipoplexes 
 Different types of lipoplexes were prepared in this work for the study of their 
physical characteristics and determine possible advantages in processes such as 
cellular internalization, cytotoxic effects and silencing efficiency. All the lipoplexes 
were formed with the same liposome formulation - DODAB:MO (2:1), with siRNA 
alone, or combinations of siRNA with pDNA, siRNA with poly-L-glutamic acid 1 (PG1, 
with 3000 to 1500 mol. wt.) and siRNA with poly-L-glutamic acid 2 (PG2 with 1500 to 
5000 mol. wt.). The physical characteristics of lipoplexes with pDNA alone and PGA 
alone were also analysed by dynamic light scattering.  A list of the different lipoplexes 
prepared is presented in Table 2. 
 
Table 2- Different lipoplex conditions prepared throughout this work. 
Lipoplexes 
DODAB:MO (2:1) + siRNA 
DODAB:MO (2:1) + pDNA 
DODAB:MO (2:1) + PG1 
DODAB:MO (2:1) + PG2 
DODAB:MO (2:1) + siRNA and pDNA 
DODAB:MO (2:1) + siRNA and PG1 
DODAB:MO (2:1) + siRNA and PG2 
  
 siRNA and pDNA are composed by nucleotide bases, each containing a 
negatively charged phosphate group. The L-glutamic acid units in PG are also 
negatively charged due to a free y-carboxyl group. siRNA, pDNA and both PG polymers 
where prepared in HEPES buffer (25 mM, pH 7.4), to have the same negative charge 
concentration. As for all the experiments the concentration of siRNA, pDNA and both 
PG was maintained in all solutions, lipoplexes containing combinations of siRNA with 
pDNA, PG1 or PG2 present twice the amount of negative charges when compared to 
solutions containing only siRNA, pDNA, PG1 or PG2. This means that lipoplexes with 
siRNA+pDNA, siRNA+PG1 and siRNA+PG2 where prepared with twice the amount of 
lipid, in order to obtain the same charge ratio (+/-).  
 The ammonium groups present in DODAB confer a positive charge to this 
molecule, which will strongly interact with DNA, siRNA and PG due to their negatively 
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charged molecules. The balance between charges of the lipoplexes formed is given by 
the charge ratio (+/-):  
 
                   
                          
                          
    Equation (2) 
 
 For the preparation of the lipoplexes, DODAB:MO (2:1) liposomes prepared by 
ethanol injection were added to the siRNA, siRNA+pDNA and siRNA+PG1/2 solutions, 
followed by an incubation period of 20 min, at room temperature (RT), with occasional 
agitation. Lipoplexes with different charge ratios were obtained. 
4. Dynamic Light Scattering (DLS) 
4.1 Size measurements 
 The mean size diameter (z-average) and polydispersity index (PDI) of the 
lipoplexes prepared were measured by Dynamic Light Scattering (DLS). Particles 
suspended in a liquid are never stationary, because their collision with solvent 
molecules leads to a constant movement. This movement is known as Brownian 
motion. Using a Malvern Zetasizer Nano SZ particle analyzer (Malvern Instruments), 
the Brownian motion of the nanoparticles can be analysed, as well as the homogeneity 
of the sample. A laser beam illuminates the sample and analyses the intensity 
fluctuations in the scattered light due to nanoparticle movement. The speed of the 
Brownian motion is different for different particle sizes: smaller particles move faster 
than large particles, which changes the fluctuation intensity. The relationship between 
the particles speed and diameter is explained by the Stokes-Einstein equation 
(Equation 3): 
  
   
    
  Equation (3) 
where (D) is the particle diffusion coefficient, (kB) Boltzmann constant (1.38 × 10-23 
m
2
.kg.s
-2
.K
-1), (T) is the temperature, (r) the radius of the particle and (η) the medium 
viscosity [79]. 
 The polydispersity index (PDI) refers to the size distribution of the liposomes, 
high PDI values (PDI>0.5) indicate that the sample has a very broad size distribution, 
while low values (PDI<0.5) are associated with monodisperse samples. When samples 
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present a high polydispersity (PDI>0,5), the Z-average value is not reliable and a 
distribution analysis data should be used instead, to determine the mean size of the 
nanoparticles [80]. 
4.2 ζ-Potential measurements 
 The ζ-Potential measurements were performed in a Malvern ZetaSizer Nano ZS 
particle analyzer. Particles in suspension acquire an electrical charge on at their surface 
that is divided in two layers: the inner layer (stern layer) is formed by ions strongly 
bond, while the outer layer has ions linked by a weak interaction (Fig.6). In this outer 
layer, the ions and particles form a stable entity, so when the particle moves, only the 
ions forming this stable entity move with it. The potential of these ions is known as ζ-
potential, and can be determined by applying an electric field to the sample. This will 
give the charged particles an electrophoretic mobility that can be measured by Laser 
Dopller Velocimetry (LDV), by pointing a laser beam to the sample and detecting the 
fluctuations on the scattered light that is proportional to the velocity of the particles. 
The relation between the electrophoretic motion and the particle's ζ-Potential is 
obta ned by the appl cat on o  the Hen y’  equat on (Equation 4): 
 
   
          
  
   Equation (4) 
 
where (Ue) is the electrophoretic mobility,     is the dielectric constant,     the zeta 
potential, ( ) is the viscosity of the medium and f(Ka) is the Hen y’   unct on, wh ch 
generally presents two different values, either 1.5 or 1 [80]. 
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Figure 10 - Representation of the electrical double layer surrounding particles dispersed in a aqueous solution. 
The boundary that divides the strongly bond inner region (stern Layer) and the diffuse outer region has a potential 
known as ζ-Potential [80]. 
4.3 Liposomes and lipoplexes Z-average and ζ-Potential 
 The mean size and surface charge of the liposomes prepared by the different 
methods described were analysed by DLS, in order to determine which liposome 
preparation method promotes more suitable characteristics for siRNA delivery into 
cells. In order to analyse the mean size, 200 µL of liposomes were pipetted into 
disposable polystyrene cuvettes, and diluted with 800 µL HEPES buffer (25 mM, pH 
 .4) be o e mea u ement at      C. Z-average, polydispersity index (PDI) and error 
values were taken in consideration. After the size analysis, 800 µL of the samples were 
pipetted into universal dip cells (Malvern Instruments) for ζ-Potential determination at 
     C. The Malvern Dispersion Technology Software (DTS) was used for data 
processing, and the ζ-Potential average and error values were taken into 
consideration. 
5. Dynamics of siRNA encapsulation by DODAB:MO (2:1) liposomes   
 Lipoplexes described before, were prepared with different charge ratios (+/-) 
and analysed by DLS and RiboGreen® assay to characterize the dynamics of siRNA 
complexation rate by DODAB:MO (2:1) liposome formulation. 
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5.1 Dynamic Light Scattering 
 Lipoplexes were prepared by adding growing amounts of DODAB:MO (2:1) 
liposomes to siRNA, pDNA, PG1, PG2, siRNA+pDNA, siRNA+PG1 and siRNA+PG2 
solutions, in order to form different charge ratios (+/-). The siRNA used for DLS and ζ-
potential measurements was a single stranded scrambled siRNA (siSCRAMB) 
containing 22 nucleotide bases, at a concentration of 4 µM. After a 20 min incubation 
period at RT, 200 µL of lipoplexes were diluted with 800 µL HEPES buffer (25 mM, pH 
7.4), and the Z-average, PDI and ζ-Potential were measured by DLS, using a Malvern 
Zetasizer Nano ZS.  
5.2 RiboGreen assay 
 Although the RNA concentration in solution can be determined by absorbance 
at 260 nm, there are important disadvantages associated with this commonly used 
technique, like poor sensitivity and interference from contaminating components such 
as nucleotides, proteins and salts in the RNA solution. To make a more accurate siRNA 
quantification, the RiboGreen assay, based on an ultra-sensitive fluorescent nucleic 
acid stain, was used. RiboGreen alone exhibits a poor fluorescence, but when it bounds 
to nucleic acids, the dye fluoresces with several orders of magnitude greater than the 
unbound form. This allows for a rapid and simple procedure for measuring RNA 
concentration in solution [81], [82]. If siRNA is encapsulated within the liposome, 
RiboGreen will exhibit a low fluorescence signal, since there are no free siRNA 
molecules to attach to. 
 In the RiboGreen assay, lipoplexes were prepared by adding increasing 
amounts of DODAB:MO (2:1) liposomes to siRNA alone, siRNA+pDNA and siRNA+PG, in 
order to obtain lipoplex solutions with charge ratios (+/-) 1, 2, 3, 5, 10 and 15. The 
lipoplex dispersions were diluted fivefold with HEPES buffer (25 mM, pH 7.4), and 100 
μL of these mixtures were transferred into a 96 black well plate (Corning, USA). A 
sample containing only siRNA diluted in HEPES buffer (25 mM, pH 7.4)  was used as a 
negative control. Afterwards, 1   μL of a 200-fold diluted RiboGreen® was added to 
each well. After 5 min incubation in the dark, the fluorescence was assessed on a 
Fluoroskan Ascent FL (Thermo Scientific) microplate fluorometer and luminometer, 
w th an e c tat on/em    on   lte  pa   o  λex=4   nm, λem=538 nm. 
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6. Cell lines and culture conditions  
 Highly transfectable derivative of human embryonic kidney (293T cells) and 
Human breast carcinoma (MDA-MB-468) cell lines where cultured in Dulbecco's 
minimal essential medium (DMEM), supplemented with 10 % (v/v) heated inactivated 
fetal bovine serum (FBS), 1 % (v/v) penicillin-streptomycin, 1 % (v/v) L-glutamine and 1 
% (v/v) sodium piruvate. 293T/GFP-Puro (siEGP) Cell line was also cultured in the same 
medium, supplemented with 2 µg/mL puromicyn for selection. The cells were kept in 
25 or 75 cm2 tissue culture flasks, in an incubator with 5 % CO2 and at 3  ˚ . In o de  to 
maintain sub-confluence, all cell lines were subcultured regularly using 0.05 % Trypsin 
solution. All work with cell lines was performed in sterile conditions in a laminar flux 
chamber Bio II A (Telstar), to avoid contaminations.  
6.1 Lipoplexes cellular uptake 
 The lipoplexes cellular internalization was determined on the 293T and MDA-
MB-468 cell lines. Lipoplexes were prepared at charge ratios (+/-) 5 and 10, with 
liposomes labelled with NBD-PE (N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-
dipalmitoylsn-glycero-3-phosphoethanolamine), and sterilized by filtration with a 0.22 
µm pore sized filter before addition to the cells. The labelled liposomes (3 mM) were 
prepared by adding 2 % (mol:mol) NBD-PE to the lipid mixture prior to ethanol 
injection. NBD-PE is composed of a phospholipid (PE) labelled in the head group by a 
fluorophore (NBD). NBD-PE will be incorporated in the liposomes and therefore allow 
internalization measurements in the cells. 
 293T and MDA-MB-468 cell lines where seeded into 24-multiwell plates (TPP, 
Switzerland) at a cell density of       cells per well in complete cell culture medium. 
293T cells were incubated 24 h and MDA-MB-468 48 h in 5 % CO2 and 3  ˚ , and then 
 ept at 4    C for 30 min, before lipoplexes were added to synchronize cell's metabolism. 
Scrambled siRNA (siSCRAMB) was used to prepare the lipoplexes and the final siRNA 
concentration on each well was set to 25nM. Immediately before the addition of siRNA 
lipoplexes, siRNA/pDNA lipoplexes and siRNA/PG lipoplexes, the complete cell culture 
medium was replaced by HBSS (Hank's Balanced Salt Solution), in order to avoid 
interferences caused by the medium components on the fluorescence measurements. 
Lipoplexes were incubated for 6 h 
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6.1.1 Fluorescence Spectrophotometry 
 After the incubation period, medium was removed and cells washed twice with 
PBS to remove any non-internalized lipoplexes. PBS was removed, 500 μL Triton X-100 
(5 %) was added to the wells to lyse the cells, and 200 μL of each sample was added to 
a 96 black well plate (Corning, USA). A negative control was done by simply adding 
triton X-100 (5 %) to cells without lipoplexes. In order to quantify the amount of NBD-
PE internalized by the cells, a calibration curve was done by successively diluting the 
concentration of NBD-PE labelled DODAB:MO in Triton X-100 (5 %). Samples were 
analysed in a Synergy Mx Multi-Mode Plaque Reader with Gen5TM software (Bio-Tek 
In t ument , Inc., EU ), w th λex=480 nm and λem=530 nm. Uptake experiments were 
performed in triplicate and. The concentration of the lipid internalized was determined 
using the calibration curves. The percentage of cellular internalization was determined 
after subtracting the fluorescence intensity of the negative control, and considering 
the total amount of lipid added to each well as the total amount of fluorescence. 
6.1.2 Fluorescence microscopy 
 After incubation, HBSS was removed from the wells, and MDA-MB-468 cells 
were washed twice with PBS. Afterwards, cells were stained with Hoechst Stain 
solution, a fluorescent DNA stain with λex≈3   nm, λem≈46 nm [83]. After 15 minutes 
incubation, PBS was removed and cells were washed three times with an acidic buffer 
(0.2M glycine–0.15M NaCl, pH 3.0), to promote the removal of liposomes attached to 
the cell-surface. Samples were analyzed by fluorescence microscopy in an Olympus 
IX71 inverted microscope with Cell F software. Bright field micrographs and 
fluorescence micrographs (FITC filter, λex=49  nm, λem=520 nm and DAPI filter, λex=372 
nm, λem=456 nm.) were acquired with 40x objective for each sample.  
6.2 Cytotoxicity assay 
MTT (3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) is a 
tetrazolium salt permeable to the cell membrane. Once inside the cells, if they are 
viable, MTT tetrazolium salt is metabolized by mitochondrial dehydrogenase enzyme 
activity into insoluble formazan coloured crystals. This crystals absorb light at a wave 
length of 570 nm, which can be easily assessed by absorption measurements. This way,  
MTT is a rapid method to assess the cell viability, since cells with a compromised 
metabolism will not metabolize the salt, and present lower light absorption [84]. 
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Both 293T and MDA-MB-468 cell lines were used to evaluate the liposomes and 
lipoplexes cytotoxicity. DODAB:MO (2:1) liposomes were freshly prepared by ethanol 
injection and sterilized by filtration through a 0.22 µm pore sized filter. For 293T cell 
line, lipoplexes were prepared at charge ratios (+/-) 10, and the siRNA final 
concentration in the well was 25 nM and 50 nM. Liposomes, siRNA, pDNA and both PG 
molecules were also tested individually in this cell line to evaluate their toxicity. For 
MDA-MD-468 cell line, lipoplexes were prepared only with 25 nM siRNA, at charge 
ratio (+/-) 5 and 10.  
Cells were seeded into 24 well plates (TPP, Switzarland) at a cell density of 
     cells per well, and incubated for approximately 24 h at 5 % CO2 and 3 ˚ . After 
the incubation period, the cell culture medium was replaced by 400 µL fresh medium. 
Then, 100 µL of the different lipoplex suspensions were added to the wells, in 
duplicates. A cell viability control was done by adding 500 mL of fresh medium to the 
cells, while a cell death control was done with 30 % (v:v) DMSO. 
The lipoplexes were incubated for 48 h, after which 50 µL of MTT (5 mg/mL) 
was added to each well and left to incubate for 1 h at 5 % CO2 and 3 ˚ , for formation 
of the formazan crystals. The medium was then  emoved and     μL of a 
DMSO/Ethanol [1:1 (v/v)] solution was added to each well to dissolve the crystals. 200 
μL of each condition was transferred into a 96 well plate (Nunc, Thermo scientific, 
USA), and 200 µL of DMSO/Ethanol [1:1 (v/v)] was used as blank. The absorbance 
measurements were done in a SpectraMax Plus 384 absorbance Plate Reader 
(Molecular Devices), with the SOFT Max Pro software. 
6.3 Gene silencing assays 
 Different methods were used to analyse the lipoplex gene silencing efficiency in 
the two cell lines. 293T cells stably expressing the EGFP protein (293TeGFP) were used 
to evaluate DODAB:MO (2:1) silencing efficiency by the decrease in the EGFP 
fluorescence signal, using fluorescence microscopy. DODAB:MO (2:1) silencing 
efficiency on MDA-MB-468 cell line was analysed by knocking down the epidermal 
growth factor receptor (EGFR) expression, using quantitative Real Time PCR (qPCR). 
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6.3.1 Fluorescence microscopy  
 The green fluorescent protein (GFP) of the jellyfish Aequorea victoria is 
commonly used as a marker for gene expression and protein localization in a variety of 
organisms. This protein absorbs light with an excitation maximum of 395 nm, and 
fluoresces at an emission maxima of 508 nm, exhibiting bright green fluorescence [85]. 
In this work we used a siRNA anti EGFP (siEGFP) to evaluate the transfection efficiency 
of DODAB:MO (2:1) lipoplexes on 293TeGFP cells, by knocking down the EGFP 
expression. The decrease in green fluorescence was observed by fluorescence 
microscopy and measured using the Image J software. 
293TeGFP cells were seeded into 24 well plates (TPP, Switzerland), at a cell 
density of      cells per well, and left over-night at 5 % CO2 and 3 ˚  for adhesion. 
Liposomes were freshly prepared as described above and filtered through a 0.22 µm 
filter for sterilization. siRNA, siRNA+pDNA, siRNA+PG1 and siRNA+PG2 lipoplexes were 
prepared at charge ratios (+/-) 5 and 10, and the siRNA final concentration in the wells 
was set to 25 nM and 50 nM. After 20 min incubation, the cell culture medium was 
replaced by 400 µl of fresh medium, and 100 µL of each lipoplex formulation was 
added to the wells, in duplicates. Lipofectamine, a common lipofection reagent with 
relatively high transfection efficiency, was used as a positive control, whilst non 
encapsulated siRNA was added to the wells as a negative control.  
After a 48 h incubation period, cells were washed with PBS and analyzed by 
fluorescence microscopy in an Olympus IX71 inverted microscope with the Cell F 
software. Bright field micrographs and fluorescence micrographs (FITC filter, λex=490 
nm, λem=520 nm) were acquired with 10x objective for each sample, in duplicate. The 
exposure time was maintained in all fluorescence photographs taken. 
The Image J software image processing program was used to count the number 
of cells in bright field micrographs, and to determine the fluorescence intensity on FITC 
micrographs. Cell count was performed through the enhancement of the contrast 
between cells and extracellular medium, achieved by removing the background and 
adjusting image threshold, and by using Analyze Particles function, which counts the 
number of cell nuclei with sizes within a range of pre-established pixels. To quantify 
the fluorescence intensity, background fluorescence was removed and the 
fluorescence micrographs converted to multi-channel composite images in order to 
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split the channels. RGB pictures are composes of red, green and blue channels, and by 
splitting the channels, the red and blue interference can be removed. Fluorescence 
intensity was quantified using the function histogram. Finally,  for each condition, the 
fluorescence intensity was divided by the number of cells counted on the 
corresponding bright field micrographs, which gives the ratio of total fluorescence 
intensity per number of cells.  
6.3.2 Reverse transcription and quantitative real time PCR (qPCR) 
For qPCR, MDA-MB-468 cells were seeded into 12 well plates (TPP, switzerland) 
at a cell density of       cells per well, and left approximately 48 h in an atmosphere 
of 5 % CO2 and 3  ˚ . DODAB:MO (2:1) Liposomes were prepared as described above, 
filtered through a 0.22 µm pore sized filter for sterilization, and added to siRNA, 
siRNA+pDNA, siRNA+PG1 and siRNA+PG2 to form lipoplexes at C.R. (+/-) 5. siRNA anti 
EGFR protein (siEGFR) was used, and lipoplexes prepared in order to have a final siRNA 
concentration of 50 nM in the wells. After 20 min incubation for the formation of 
lipoplexes, cell culture medium was replaced by 900 µl fresh medium, and 100 µl of 
each lipoplex formulation was added to the wells. Cells without lipoplexes were used 
as a negative control, to have the normal expression of EGFR, while, Lipofectamine was 
used as a positive control. After a 24 h incubation period, EGFR down regulation was 
analyzed by qPCR, using GADPH as the reporter gene. 
6.3.2.1 RNA Isolation 
 PCR is often used for the quantification of miRNAs and other regulatory RNAs, 
cellular mRNA and mRNA splice variants [86]. In order to analyse changes in gene 
expression by real time polymerase chain reaction (RT-PCR), first it is necessary to 
extract the mRNA from the cells and convert it to complementary DNA (cDNA) by 
reverse transcriptase (RT). Since the mRNA obtained after extraction is extremely 
sensitive and prone to degradation, it is important to work under tightly controlled and 
well defined conditions to avoid mRNA degradation. RNA purity and integrity must also 
be analysed before reverse transcription, since impurities in RNA sample may lead to 
the inhibition of PCR reaction or to inaccuracies in gene expression evaluation. RNA 
quality can be assessed by various absorbance measurements such as NanoDrop [87].  
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 RNA isolation was performed using a SV Total RNA Isolation kit (Promega, USA) 
according to manufacturer's instructions. Briefly, DMEM medium was removed, cells 
were washed with PBS ice cold and collected in RNA Lysis Buffer into sterile tubes, to 
which RNA Dilution Buffer was added. After a heating step (70 ˚C for 3 min), the tubes 
were centrifuged (10 min at 12000 rpm) and the cleared lysate transferred into fresh 
tubes. 95 % ethanol was added, the mixture is transferred into a Spin Basket Assembly 
and centrifuged for 1 min at 12000 rpm. The eluates were discarded and the DNase 
incubation mix (Yellow Core Buffer solution, MnCL2 at 0.09 M and DNase I) was added 
to the membranes of the spin basket. After 15 min at RT, DNase Stop Solution was 
added to the membranes and a centrifugation of 1 min at 12000 rpm performed.  RNA 
Wash Solution was used to wash the membranes several times and, finally, RNA was 
eluted with Nuclease-Free Water. Isolated RNAs were quantified with the Nanodrop 
ND-1000 spectrophotometer. Absorbance ratios of 260/280 and 260/230 were 
determined to check the purity of the RNA samples 
6.3.2.2 Reverse Transcription 
 For reverse transcription a mixture containing dNTPs, random primers and 
RNase H must be prepared and added to the extracted RNA, so that the enzyme 
reverse transcriptase RNase H+ will promote the conversion of RNA to cDNA. The 
amount of siRNA must be equal for every sample in order to obtain reliable results.  
 Reverse transcription was performed using the  Sc  pt™ Reve  e T an c  pt on 
Supermix for qPCR kit (BioRad, USA). This supermix contains all the necessary 
components for reverse transcription (reverse transcriptase, RNase inhibitor, dNTPs, 
oligo(dT), random primers, buffer, MgCl2 and stabilizers), except the RNA template. 
The  eact on wa  pe  o med acco d n  to manu actu e ’   n t uct on , and the RN  
concentration normalized to 1 µg for all the samples, using nuclease-free water to 
adjust the final reaction volume to 20 µl. The complete mixture was incubated in a 
T100  thermal cycler (Bio-Rad, USA) and the following protocol established: 5 min at 25 
°C to allow the binding of the primers, followed by 60 min at 42 °C to promote optimal 
conditions for reverse transcription, and finally 5 min at 85 °C to inactivate the reverse 
transcriptase. 
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6.3.2.3 qPCR 
 Quantitative Real-time PCR (qPCR) is a widely used technique to analyse and 
quantify differences in gene expression levels between samples. qPCR is performed on 
single or double-stranded DNA templates. For qPCR to occur, a mixture must be 
prepared containing: two oligonucleotide primers that attach to the DNA sequence 
and promote amplification; the four deoxynucleotide triphosphates dNTPs; DNA 
polymerase, which extends the primers by incorporating the dNTPs; magnesium ions; 
and a dye or dye-labelled probe that allows the miniaturization of the amplification 
and quantification of its products in real time. Asymmetric cyanine dyes such as SYBR 
Green I and BEBO are often used as reporters for qPCR [88]. The method is based on 
repeated heating and cooling cycles, where high temperature is applied in order to 
promote the separation of the DNA double strand, and temperature is lowered to 
allow the binding of the primers to the template. The last step involves the application 
of high temperatures (72 ˚C) which are ideal for polymerase function [86][88][89]. In 
qPCR experiments, various reference genes such as glyceraldehyde-3-phosphate 
dehyd o ena e (G   H), β-actin or rRNA are used as an internal standards, which are 
assumed to have constant expression between experimental conditions. This way, 
experimental data can be normalized to the reference gene in each sample [90]. A 
series of guidelines known as MIQE guidelines were written to establish par1ameters 
that should be met to publish acceptable results from qPCR experiments [91].   
 Real-Time PCR was performed using the iTaq Universal SYBR Green Supermix 
(Bio-Rad, USA). For each condition, 1 µl of EGFR primer forward at 10nM and EGFR 
primer reverse were added to the iTaq Universal SYBR Green Supermix containing the 
antibody-mediated hot-start iTaq polymerase, dNTPS, MgCl2, SYBR Green I dye, 
enhancers, and stabilizers. After the prepared mixture was loaded into a 96-well PCR 
plates (iCycler iQ, Bio-Rad), 1 µl cDNA template of each condition was added to each 
well, and the final reaction volume normalized with DNase free H2O. The mixture was 
prepared on ice, to avoid sample degradation and mixture components were carefully 
pipetted,  to avoid contaminations that would alter the results. The same protocol was 
followed using primers for the endogenous reference gene GADPH ( o wa d p  me   ′-
AGGTCGGTGTGAACGGATTTG-3′ and reverse primer  ′-
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TGTAGACCATGTAGTTGAGGTCA-3′), for normalization of the cDNA expression in each 
condition.  
 The qPCR reaction was performed in the CFX96 Touch Real-Time PCR Detection 
System (Bio-Rad), by applying one cycle of 5 min at 95 °C, followed by 40 cycles of PCR 
at 95 °C × 15 s and 60 °C × 30 s. A melting curve (1 cycle of 95 °C × 60 s and 
55 °C × 60 s, followed by an increase in temperature from 55 to 95 °C, with 0.5 °C 
increments in each step) was made immediately after the reaction, to demonstrate the 
specificity of the amplification. No template controls were evaluated for each target 
gene. Quantification cycle (Cq) values were generated automatically by the Bio-Rad 
CFX Manager 2.0 Software, and the relative gene expression values were determined 
according to Equation 4 [92]: 
      
       
         
    
       
     Equation (5) 
where Etarget is the real-time PCR efficiency of the EGFR transcript; Eref is the real-time 
PCR efficiency of the GADPH reference gene transcript; ∆Cqtarget = Cqcontrol - Cqsample of 
the target gene transcript; and ∆Cqref = Cqcontrol – Cqsample of the reference gene 
transcript. After a calibration curve was done for both genes, PCR efficiencies were 
calculated according to E =10(–1/slope), and found to be between 94 % and 112 %, with 
R2 > 0.99. 
7. Statistical analysis 
Prior to data analysis all assumptions were met testing for normality (Shapiro-
Wilk test) and homo ene ty o  va  ance  (Levene’  te t).  
To investigate the influence of different lipoplexes on GFP silencing of 
293T/GFP-Puro cell line, a three-level nested design ANOVA was conducted: 
composition: DODAB:MO (2:1) liposomes and siRNA-related systems; charge ratio (+/-
): 0, 5 and 10; concentration: 25 nM and 50 nM.  
ANOVA model [two factors: composition (five levels: siRNA lipoplexes, siRNA 
coupled with small mol weight poly-glutamate lipoplexes, siRNA coupled with large 
mol weight poly-glutamate lipoplexes, siRNA coupled with pDNA lipoplexes, and death 
control) and concentration (two levels: 25 nM and 50 nM)] was conducted to 
determine differences on metabolic activity of 293T cells, pre-exposed to the different 
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lipoplexes. In vitro cytotoxicity (MTT assay) of the lipoplexes single components was 
further investigated for this cell line, following the same statistical analysis: ANOVA 
model [two factors: type (seven levels: DNA, small mol weight poly-glutamate, large 
mol weight poly-glutamate, siRNA, siRNA liposomes, liposomes and death control) and 
concentration (two levels: 25 nM and 50 nM)]. The lipoplexes interference on 
metabolic activity of MDA-MB-468 human breast carcinoma cells was also investigated 
following, a two-level nested design ANOVA: composition: DODAB:MO (2:1) liposomes 
and siRNA lipoplexes, and charge ratio (+/-): 0, 5 and 10. To investigate differences on 
cellular metabolic activity among human cells of different origin, a two-level nested 
design ANOVA was considered: cell line: 293T cells and MDA-MB-468, and condition 
(25 nM; C.R. (+/-) 10): DODAB:MO (2:1) liposomes and siRNA lipoplexes. All data were 
tested for differences among replicates of different-time performed experiments using 
a MANOVA design. 
Post hoc comparisons were conducted using Student-Newman-Keuls. A P value 
of 0.05 was used for significance testing. Analyses were performed in STATISTICA 
(StatSoft v.7, US). 
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III - Results and Discussion 
In this study liposomes prepared by three different methods were analysed by DLS in 
order to select the most suitable method to develop a new siRNA delivery system 
based on DODAB:MO (2:1) liposomes. After choosing liposome preparation method, 
DODAB:MO (2:1) lipoplexes encapsulating siRNA, and co-encapsulating siRNA+pDNA, 
siRNA+PG1 and siRNA+PG2 were formed. Different parameters such as Z-average, ζ-
potential, siRNA encapsulation efficiency, cellular uptake, cytotoxicity and silencing 
efficiency were assessed for all lipoplex formulations, in order to understand if the 
addition the anionic cargo (pDNA or PG) to the lipoplexes could promote substantial 
differences in such parameters. 
1. Liposome Preparation Method 
 DODAB:MO (2:1) liposomes were prepared by three different methods: ethanol 
injection, sonication and extrusion after lipid film hydration. Liposomes obtained for 
each method were analysed by Dynamic and Electrophoretic Light Scattering (DLS) to 
understand how these methods affect their physicochemical properties, such as size 
and surface charge. 
1.1 Sonication 
 Sonication by ultrasonic bath was the first method tested, using different 
amplitudes and times of exposure. The size and polidispersity index (PDI) of the 
liposomes obtained were measured by DLS (Table 3). 
Table 3 - Liposome mean size diameter (nm) and PDI values obtained after different amplitudes (A) and times of 
exposure to sonication. 
A (%) Time (min) Size (nm) PDI 
60 5 268.5 0.498 
10 101.4 0.472 
20 94.23 0.434 
70 5 91.14 0.266 
10 81.72 0.282 
20 78.14 0.242 
80 5 126.9 0.432 
10 83.69 0.366 
20 62.24 0.262 
90 5 118.6 0.289 
10 79.11 0.289 
20 70.43 0.233 
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 Ultrasonic bath sonication leads to the formation of liposomes with a 
hydrodynamic diameter ranging from 70 to 270 nm. The results presented in Table 1 
show that increasing the amplitude and time of exposure during sonication resulted in 
smaller liposomes and lower PDI values. Despite the particle size obtained being 
suitable for application in gene therapy, the high PDI values obtained (0.25 to 0.5 for 
most liposome formulations) are not ideal. In addition to the high PDI value, liposomes 
prepared by this method presented very low stability, since only a few hours after 
preparation, it was possible to see the increase of turbidity in the samples, possibly 
due to aggregation, reorganization into multilamellar structures and precipitation of 
the liposomes. DLS measurements showed that smaller sized liposomes have 
aggregated into larger ones (data not shown), and this aggregation behavior can be 
linked to the inability of smaller liposomes to promote electrostatic repulsion with 
surrounding liposomes. Another hypothesis is that sonication method may promote 
hydrophobic defects in the liposomes which might be responsible for the aggregation 
observed [61]. Even though the mean size diameter of liposomes obtained by 
sonication was considered suitable for encapsulation and delivery of nucleic acids, this 
preparation method presents several disadvantages, such as the lack of reproducibility 
between batches, the lack of homogeneity between liposomes and the particle's 
aggregation behavior observed. Due to these disadvantages, no further studies were 
made with liposomes prepared by sonication. 
1.2 Extrusion and Ethanol injection 
 After excluding the sonication method, another two methods were tested, lipid 
film hydration followed by extrusion and ethanol injection. The mean size diameter 
and ζ-potential of liposomes obtained by these methods were analyzed by Dynamic 
and Electrophoretic Light Scattering (Fig.11A, B). 
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Figure 11 - DLS measurements of liposomes prepared by extrusion and injection methods. (A) shows the Z-
average (nm) and polidispersity (PDI) of liposomes prepared by extrusion and injection and (B) shows the ζ-potential 
values (mV) for both methods. 
 Fig. 11A shows the mean size (nm) and PDI of DODAB:MO (2:1) liposomes 
prepared by ethanol injection and lipid film hydration followed by extrusion. No 
significant size differences can be observed in liposomes obtained by either method: 
both liposomes present relatively small hydrodynamic diameter (around 160 nm). 
L po ome  p epa ed by e t u  on  howed lowe    I (≈ . ),  u  e t n  that th   
preparation method promotes a more uniform size distribution compared with 
ethanol inject on method, wh ch p e ent  a  elat vely h  h   I (≈ .  ) value. 
Liposomes prepared by ethanol injection present similar physicochemical 
characteristics as observed in previous work from our group [93]. As for extrusion, 
liposome sizes and mainly PDI values obtained were slightly higher than the ones 
previously reported for the same DODA:MO (2:1) formulation [54]. These differences 
might be associated with technical problems. 
 The superficial charge of the particles obtained is an important physicochemical 
property. Fig. 11B presents the ζ-potential of liposomes prepared by both methods. As 
expected, liposomes present a highly positive surface charge due to the presence of 
the cationic lipid DODAB. Liposomes prepared by extrusion present a slightly higher 
value of ζ-potential (≈6 .3 mV) than l po ome  p epa ed by ethanol  nject on (≈  .4 
mV). This additional superficial charge can be the result of conformational changes in 
the liposomes during extrusion, with MO relocating to the interior of the liposomes. 
The high ζ-potential values can improve the particle's ability to encapsulate nucleic 
acids and promote cell entry through electrostatic attraction. However, positively 
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charged particles also present higher cytotoxicity and are easily cleared when applied 
in vivo, due to the interaction of serum proteins which might  trigger the immune 
system  [35], [94], [95].  
 Liposomes prepared by both methods present roughly the same size and ζ-
potential, yet, extrusion is a more reproducible method to obtain stable and 
homogenous liposome formulations with appropriate and adjustable sizes. However, 
retention of lipid in the polyester filters during extrusion is a main disadvantage of this 
method. The retention of lipid can greatly influence DODAB:MO ratios as well as the 
concentration of liposomes in solution. These alterations, if not measured, interfere 
with all the following experiments. Therefore, ethanol injection was the chosen 
method to proceed with the rest of the experiments of this thesis.  
2. Dynamics of nucleic acid encapsulation 
 One of the main objectives of this work is to study how the addition of pDNA or 
of PG molecules to siRNA lipoplexes influences the final structure of lipoplexes. 
DODAB:MO (2:1) liposomes encapsulation rate of siRNA, with either pDNA, PG1 or 
PG2, was studied by DLS and Ribogreen assay. 
2.1 Dynamic Light Scattering 
 Lipoplexes with different C.R. (+/-) (1, 2, 3, 4, 5 and 10) were prepared for each 
condition, and Z-average and ζ-potential measurements were performed in order to 
characterize the different lipoplexes formed and to understand if the addition of 
anionic charges (pDNA and PG) to the mixture influences the complexation efficiency 
of DODAB:MO (2:1) liposomes. 
44 
 
 
Figure 12 - DLS measurements of different lipoplexes prepared at increasing C.R. (+/-). Z-average, polidispersity 
and ζ-potential measurements of siRNA lipoplexes,  siRNA+pDNA lipoplexes, siRNA+PG1 and siRNA+PG2 lipoplexes, 
prepared with 4µM siRNA in HEPES buffer, 25mM, pH 7.4.. 
 Fig. 12  shows the size measurements of lipoplexes prepared wih siRNA alone 
showed an increse in lipoplex mean size diameter and PDI up to C.R. (+/-) 3, and a 
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subsequent reduction of both parameters for higher C.R. (+/-). When pDNA or PG2 are 
added to the mixture, the increase in mean size diameter and PDI occurs at C.R. (+/-) ≤ 
2. For higher C.R.s (+/-), lipoplex mean diameter and size distribution is reduced and 
maintained. For lipoplexes with PG1 and siRNA, the mean size diameter reaches its 
peak at C.R. (+/-) 1 and is reduced until C.R. (+/-) 3. For higher charge ratios, no 
significant alteration is observed. The high PDI of siRNA+PG1 lipoplexes at C.R. (+/-) 4, 
5 and 10 can be related to a less homogenous DODAB:MO (2:1) liposome batch. 
 ζ-potential measurements of siRNA, siRNA+pDNA and siRNA+PG2 lipoplexes 
 howed ne at ve value  (≈-35 mV)  for C.R. (+/-) 1 and 2. For higher C.R.s (+/-), ζ-
potential becomes positive and stabilizes around +50 mV. siRNA+PG1 lipoplexes ζ-
potential measurements only present negative values for C.R. (+/-) 1. 
 The addition of DODAB:MO (2:1) liposomes to the nucleic acid solutions 
promotes an eletrostatic attraction between the positively charged ammonium groups 
of DODAB, and the negatively charged groups of either nucleic acids or polymers. This 
attraction will promote the formation of aggregates, responsible for the increase in 
mean size observed for lipoplexes with low C.R. (+/-). ζ-potential measurements for the 
same C.R. (+/-) present negative values, which implies the presence of either free 
siRNA, pDNA and PG, or adsorbtion of these molecules to the surface of the 
aggregates. With the increase of C.R. (+/-), the excess of liposomes promotes a 
neutralization of the negative charges from the nucleic acid/polymer backbone. This 
neutralization leads to the reorganization of the  aggregates, promoting the insertion 
of siRNA inside the liposome vesicles [54]. This reorganization step is responsible for 
the maximum mean size diameter and PDI observed. This reorganization also 
promotes the encapsulation of the negatively charged nucleic acids or polymers, 
resulting in the increase of ζ-potential values. Further increase in the charge ratio 
results in smaller mean size diameters and highly positive ζ-potential values. DLS 
measurements also showed slight differences between physicochemical properties of 
lipoplexes prepared with PG1 and PG2. This differences are probably caused by the 
mean size of PG molecules. PG2 has a higher mol. wt. and, therefore, resembles pDNA 
molecules, which might explain the similarities observed between these systems. 
siRNA+PG1 lipoplexes, due to the smaller molecule size of PG1, seems to promote 
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quicker compaction of siRNA, slightly reducing the amount of lipid necessary to 
promote the neutralization of the negative charges. 
 All lipoplex formulations prepared at C.R. (+/-) > 4 present roughly the same 
 mall   ze (≈1   nm) and h  hly po  t ve  u  ace cha  e (≈+ 1 mV). The ζ-potential 
values a e   m la  to the one  obta ned  o  l po ome  (≈+  .4 mV)  u  e t n  that mo t 
of the nucleic acid or polymer molecules in the solution were efficiently encapsulated. 
However, small changes can be observed in the encapsulation rate for C.R. (+/-) < 4. 
SiRNA+pDNA, siRNA+PG1 and siRNA+PG2 lipoplexes reach stable values of ζ-potential 
and Z-average at C.R. (+/-) 3 while siRNA lipoplexes only reach stability at C.R. (+/-) 4. 
Taken together, these results show that all formulations promote siRNA encapsulation, 
and the addition of pDNA or PG molecules can reduce the amount of lipid necessary to 
efficiently encapsulate siRNA. This might be the result of an increased eletrostactic 
interaction between negative and positive charges due to the addition of anionic cargo 
to the siRNA suspension. 
2.2 RiboGreen assay 
 siRNA encapsulation efficiency of each lipoplex formulation was determined 
using the RiboGreen assay. When this probe intercalates with nucleic acids, its 
fluorescence intensity is enhanced, allowing the quantification of nucleic acids in 
solution. Lipoplexes for each condition were prepared at increasing C.R. (+/-) and 
siRNA encapsulation efficiency was determined.  
 
Figure 13 - siRNA encapsulation efficiency for each lipoplex formulation prepared at increasing charge ratios (+/-) 
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 The RiboGreen assay (Fig. 13) shows that even though at C.R. (+/-) > 5 all 
l pople   o mulat on  p omote e   c ent   RN  encap ulat on (≈9  %), the rate of 
encapsulation is slightly different for the different lipoplexes. In accordance to DLS 
measurements, lipoplexes containing PG present slightly higher encapsulation 
efficiency, and reach maximum encapsulation at lower C.R. (+/-), suggesting that the 
additional anionic charges provided by the polymer enhance siRNA compaction inside 
DODAB:MO (2:1) liposomal formulation. The differences on PG molecular size do not 
seem to promote any differences in the liposomes encapsulation efficiency. Contrarily 
to what DLS measurements showed, siRNA+pDNA lipoplexes present a lower 
encapsulation efficiency than siRNA lipoplexes, for all C.R. (+/-). This lower 
encapsulation efficiency may be due to the binding of RiboGreen to both free siRNA 
and pDNA, enhancing fluorescence signal intensity.  
 Overall, DLS and fluorescence measurements allowed to understand that 
DODAB:MO (2:1) liposomes efficiently encapsulate siRNA at C.R. (+/-) 5 or higher, and 
that the addition of anionic cargos to lipoplexes can slightly improve the encapsulation 
efficiency by reducing the amount of lipid necessary. siRNA encapsulation efficiency 
was slightly higher for C.R. (+/-) 15, however, the excess of lipid can result in high 
cytotoxicity. Therefore, only lipoplexes prepared at C.R. (+/-) 5 and 10 were tested in 
vitro for cellular uptake, cytotoxicity and silencing efficiency. 
3. Cellular uptake 
 Lipoplexes cellular internalization was evaluated by adding liposomes and 
lipoplexes, labeled with the fluorescent NBD-PE probe, to 293T and MDA-MB-468 cell 
lines. Two different C.R. (+/-), 5 and 10, were used for a final siRNA concentration of 25 
nM. Internalization in 293T cell line was analyzed by fluorescence measurements, after 
6 h incubation with liposomes and lipoplexes. For MDA-MB-468, apart from the 
fluorescence measurements, also fluorescence microscopy was used to observe the 
cellular uptake of the different lipoplexes. Three independent experiments were 
performed for fluorescence measurements in both cell lines. 
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3.1 Fluorescence measurements for evaluation of cell uptake 
 To determine the cellular uptake of liposomes and lipoplexes in 293T and MDA-
MB-468 cell lines, calibration curves of the fluorescence emission spectrum area in 
function of the lipid concentration of all systems were constructed. This way it was 
possible to estimate the labeled lipid concentration internalized by the cells. Data was 
normalized for lipid concentration present in lipoplexes or liposomes used. 
 
Figure 14 - 293T and MDA-MD-468 cellular association with NBD-labeled liposomes and lipoplexes after 6 h 
incubation. Liposomes and siRNA, siRNA+pDNA, siRNA+PG, siRNA+PG2 lipoplexes were prepared at CR (+/-) 5 and 
10, incubated at a final siRNA concentration of 25 nM. Results were normalized in function of maximum lipid 
concentration added to cells.  
 Fluorescence measurements in 293T cell lines (Fig. 14) showed a very small 
l pople   nte nal zat on pe centa e (≈  %), and no    n   cant difference between 
conditions or C.R (+/-) were detected. Liposomes and lipoplexes internalization in 
MDA-MB-468 cells (Fig. 14) was equally low, although some differences in 
internalization efficiency were observed for different C.R.s: at C.R. (+/-) 5 
internalization efficiency was approximately 2 % for every condition, while the 
liposomes and lipoplexes at C.R. (+/-) 10 resulted in a slightly higher internalization 
e   c enc e  (≈3 %). Even thou h poo   nte nal zat on e   c ency wa  ob e ved,  t    
possible to understand that no significant differences were observed due to the 
addition of an anionic cargo to lipoplexes, suggesting that cellular internalization is not 
affected by the addition of these compounds. The low uptake efficiency observed 
might be linked with a loss of cells while washing the wells with PBS, inefficient cell 
lysis promoted by Triton-X, or quenching of the fluorescence by compaction or by 
dilution of the fluorescent lipid in the cellular membrane [16]. 
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 In order to confirm if these low internalization percentages obtained by 
fluorescence measurements were accurate, MDA-MB-468 cell lines internalization 
efficiency was also analyzed by fluorescence microscopy. 
3.2 Fluorescence Microscopy 
 MDA-MB-468 cells were treated with NBD-PE labeled liposomes and lipoplexes 
prepared at C.R. (+/-) 10. After a 6 h incubation period, cells were subjected to acidic 
wash to remove non internalized particles [96] and incubated with Hoechst for nucleus 
staining. Bright field and fluorescence (DAPI and FITC) micrographs were obtained for 
each test condition. Fig. 15 shows the merging of bright field, FITC and DAPI 
micrographs. 
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Figure 15 - Merged bright-field and fluorescence micrographs of internalized NBD-labeled liposomes and 
lipoplexes by MDA-MB-468 cells. Liposomes/lipoplexes were incubated with 293T cell line at charge ratio (+/-) 10 
and final siRNA concentration of 25 nM for 6 h. Untreated cells (A), liposomes (B), siRNA lipoplexes (C), siRNA+pDNA 
lipoplexes (D), siRNA+PG1 lipoplexes (E) and siRNA+PG2 lipoplexes (F). Objective 40x was used. Scale bar represents 
20 µm. 
  
 The green fluorescence observed by fluorescence microscopy represents the 
binding and/or internalization of NBD-labeled liposomes and lipoplexes by the cells, 
while blue fluorescence is the result of Hoechst binding to DNA, labeling the cell 
nucleus. Merged micrographs allow the visualization of internalization of liposomes 
and lipoplexes co-encapsulating siRNA with pDNA or PG. Although low internalization 
is seen for siRNA lipoplexes, this lipoplex formulation presents half the amount of lipid 
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than the other formulations, explaining the low internalization efficiency observed. In 
sum, by observing these micrographs, it becomes evident that systems interact with 
the cells, and are probably internalized. These micrographs suggest that a higher 
internalization efficiency has occurred when compared to the one reported by 
fluorescence measurements, reinforcing the need to optimize this method.  
 To better understand the cellular uptake of the systems, additional 
methodologies should be used, such as flow cytometry, which would allow for better 
quantification of cellular association, and confocal microscopy, a powerful imaging 
technique that would allow a better observation of lipid nanoparticles internalization. 
4. Cytotoxicity assay 
 One of the most important parameters to evaluate the biomedical applicability 
of liposome formulations is the toxicity levels induced by these systems when 
interacting with cells. Therefore, the cytotoxicity induced by liposomes and each 
lipoplex formulation was evaluated in 293T and MDA-MB-468 cell lines. MTT assay was 
used to determine the cell's metabolic activity after 48 h incubation with lipoplexes. 
The reduction in cell metabolic activity can be used to understand the level of 
cytotoxicity induced by lipoplexes. 
4.1 293T cell line 
 Cytotoxicity induced in 293T cell lines was evaluated using lipoplexes prepared 
at C.R. (+/-) 10, at two different siRNA concentrations, 25 and 50 nM. The cytotoxicity 
of siRNA, pDNA, PG1, PG2 and liposomes was also evaluated, for the same 
concentrations as the ones used for the preparation of the complexes. Since siRNA 
concentration is maintained, lipoplexes containing siRNA alone will present half the 
amount of lipid as the other lipoplex formulations. The results were presented as the 
mean values of three independent experiments. 
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Figure 16 - Cell viability evaluation by MTT assay of individual lipoplex components (A) and different liposome 
and lipoplex formulations (B). Lipoplexes were prepared at charge ratio (+/-) 10 with 25 and 50 nM of siRNA, and 
incubated for 48 h with the 293T cell line. Liposomes (siRNA) and Liposomes were repeated in (B) to allow for better 
comparison between lipoplex systems and the liposomes used to form them. 
 The results of metabolic activity for the single compounds of the lipoplexes (Fig. 
16 A) show that siRNA, pDNA, PG1, and PG2 alone promote a very little decay in cell 
viability for both 25 nM and 50 nM concentrations. Interestingly, the liposome 
concentration needed for the preparation of siRNA lipoplexes (Liposomes/siRNA), also 
did not promote a significant decrease in cell viability for neither concentration. 
However, the liposome concentration used for co-encapsulation of siRNA with pDNA 
or PG molecules, induced a significant decrease in metabolic activity for both 
concentrations. This was expected, since co-encapsulation requires twice the amount 
of lipid, which is the main responsible for the decrease in cell viability.  When analyzing 
the percentage of metabolic activity induced by the lipoplex single components, 
significant statistical differences were observed among groups (F(6,154)=4.307, 
P<0.05), where liposomes used for co-encapsulation induced higher cytotoxicity, a 
tendency significantly different from all the other conditions (SNK, data not shown).  
 Fig. 16B shows the decrease in cell viability induced by each lipoplex and 
liposomal formulation for 25 and 50 nM. It is possible to observe that, all lipoplex 
formulation promote roughly the same cell viability (65 and 55 for 25 and 50 nM, 
respectively). siRNA+pDNA, siRNA+PG1 and siRNA+PG2 lipoplexes cytotoxicity levels 
resemble the ones obtained for liposomes, suggesting that most of the cell viability 
reduction is caused by liposome concentration, and that the addition of anionic cargo 
to lipoplexes does not influence cytotoxicity. Even though only half the amount of 
liposomes was used to encapsulate siRNA alone, the same level of cytotoxicity was 
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observed for this lipoplex formulation. Contrarily to what happens for the other 
lipoplexes, encapsulation of siRNA alone appears to promote liposome cytotoxicity. 
Statistical analysis allowed us to confirm that an increase in siRNA concentration 
caused a significantly decrease in 293T cellular metabolic activity (F(1,154)=6.432, 
P<0.05), and that no statistical differences were observed for in vitro cytotoxicity of 
the different lipoplexes (see Table 4). Also, no differences among replicates or 
different experiences were found in any case (MANOVA, data not shown). 
 
Table 4 - Factorial ANOVA results on cellular metabolic activity of 293T cells after incubation with different lipid-
siRNA based nanoparticles for 48 h. 
Source of variation DF MS F P 
cellular metabolic activity 
    Composition 4 14870.482 68.435 <0.05 
Concentration 1 5385.627 24.785 <0.05 
composition*concentration 4 425.292 1.957 0.106 
Error 110 5.832 
   
4.2 MDA-MB-468 
 MDA-MB-468 metabolic activity 48 h after administration of each lipoplex 
formulation at C.R. (+/-) 5 and 10, was measured for a final siRNA concentration of 25 
nM. Lipoplexes were not prepared with 50 nM siRNA since it was expectable that 
these formulations would induce high levels of cytotoxicity. As in the previous 
experiment, siRNA concentration was maintained, therefore for the formation of 
siRNA lipoplexes half the amount of liposomes used in the other lipoplexes was 
required. The measurements presented were obtained in two independent 
experiments. 
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Figure 17 - MDA-MB-468 cell viability, evaluated by MTT assay, after incubation with different liposome and 
lipoplex formulations for 48 h. Lipoplexes were prepared at charge ratio (+/-) 5 and 10, with 25 nM final siRNA 
concentration. 
 No significant differences in cell viability can be observed between each of the 
lipoplexes and liposome formulations prepared at C.R. (+/-)   (≈   %). The fact that all 
lipoplexes cause roughly the same cytotoxicity as the liposomes used to prepare them 
(Fig. 17), reinforces the idea that liposomes are the major parameter affecting cell 
metabolism. When lipoplexes were prepared at C.R. (+/-) 10, the increase in liposome 
concentration lead to slightly lower values of cell viability for every condition, except 
for siRNA liposomes. Cells treated with liposomes at the same concentration used to 
encapsulate siRNA plus an anionic cargo present the same cell viability values as 
l pople e  (≈  6 %) p epa ed at  .R. (+/-) 10, once again suggesting that most of the 
reduction in cell viability is caused by the lipid present in the lipoplexes. In accordance 
to what was observed with the 293T cell line, even though liposome concentration 
used to form siRNA lipoplexes presents no significant reduction in cell viability, siRNA 
lipoplexes application results in significant cell metabolism decrease, suggesting that 
the structural differences promoted by the presence of siRNA alone, result in more 
cytotoxic systems. The nested ANOVA results on metabolic activity of MDA-MB-468 
breast carcinoma line, exposed to the different lipoplex and liposome formulations, 
confirmed that a statistically significant increase in the cytotoxicity effect of siRNA 
lipoplex incubation (F(6,75)=7.889, P<0.01) occurred. Also, an increase in the charge 
ratio caused a significantly decrease in cellular metabolic activity of this line (one-way 
ANOVA, F(2,85)=1846.800, P<0.01). 
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 Both cell lines were treated with lipoplexes prepared at C.R. (+/-) 10 for a final 
siRNA concentration of 25 nM, therefore, cytotoxicity levels induced by these 
conditions can be compared between cell lines. When comparing the metabolic 
activity between the cells exposed to the different lipoplexes and liposome 
formulations, significant statistical differences were observed among groups 
(F(12,118)=83.527, P<0.01). The metabolic activity percentages of 293T cells were 
found to be lower than those of MDA-MB-468 breast carcinoma cell line (Fig. 18). The 
highest metabolic activity value was obtained for cells exposed to siRNA liposomes, a 
tendency that for 293T cell line, but not for MDA-MB-468 breast carcinoma line, is 
significantly different from all the other conditions (SNK, data not shown).  
 
 
Figure 18 Metabolic activity (MTT assay) of 293T and MDA-MB-468 cell lines exposed to liposomes and lipoplexes 
for 48 h. Lipoplexes were prepared at charge ratio C.R. (+/-) 10 with 25 nM final siRNA concentration. (*) indicate 
significant differences among treatments (P<0.05, nested design ANOVA). 
 
 Taken together, these results show that after a 48 h incubation period with 
liposomes and lipoplexes, 293T cells presented lower metabolic activity than MDA-MB-
468 cells for C.R. (+/-) 10, and 25 nM final siRNA concentration. For both cell lines the 
same tendency is maintained, with lipoplexes co-encapsulating siRNA with pDNA, PG1 
and PG2 promoting the same levels of cytotoxicity as siRNA lipoplexes, even though 
twice the amount of lipid was used to prepare the first formulations. No significant 
differences were observed between siRNA+PG lipoplexes and siRNA+pDNA lipoplexes 
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for these conditions. However, a previous study has reported that when the 
concentration is increased, siRNA lipoplexes with pDNA promote higher cytotoxicity 
when compared to siRNA lipoplexes with PG molecules, suggesting that in terms of 
cytotoxicity, addition of PG molecules to lipoplexes is preferable to the addition of 
pDNA [10], [69]. Also, the difference in PG molecular size does not seem to affect the 
cytotoxicity induced by the lipoplexes.    
5. Silencing efficiency 
 Silencing efficiency of siRNA lipoplexes was evaluated for two different cell 
lines, 293T/GFP-puro and MDA-MB-468. A different method was used to study the 
silencing efficiency of lipoplexes in each cell line. 293T/GFP-puro EGFP gene 
knockdown was assessed by fluorescence microscopy while EGFR gene silencing was 
measured in MDA-MB 468 cell line by qPCR. 
5.1 Fluorescence Microscopy 
293T/GFP-puro cells were treated with the different lipoplex formulations at 
C.R. (+/-) 5 and 10, and two different siRNA concentrations, 25 and 50 nM. However, 
cell measurements for CR (+/-) 10 and 50 nM were not performed since significant 
cytotoxicity was observed by microscopy. Fig. 19 shows representative brightfield and 
fluorescence micrographs of cells treated with the different lipoplex formulations.  
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Figure 19 - Fluorescence (1) and bright-field (2) micrographs of 293T/GFP-puro cells. cells were treated with  
liposomes and lipoplexes at charge ratio (+/-) 10 and siRNA concentration of 25nM for 48 h. Untreated cells (A), 
lipofectamine (B), siRNA lipoplexes (C), siRNA+pDNA lipoplexes (D), siRNA+PG1 lipoplexes (E) and siRNA+PG2 
lipoplexes (F). Objective 10x was used. Scale bar represents 100 µm. 
 
As expected, when compared to the control cells (A), it is visible that 
lipofectamine treatment (B) results in accentuated decrease in fluorescence intensity, 
which is the result of the EGFP protein silencing by siEGFP. A smaller decrease can be 
observed for lipoplexes where siRNA is co-encapsulated with pDNA or PG (D, E and F), 
whereas for siRNA lipoplexes (C) no significant decrease in fluorescence intensity can 
be observed. Fluorescence intensity values were measured using Image J software, and 
the results were statistically analyzed (Fig. 20). 
The nested design ANOVA results on EGFP silencing percentage of 293T/GFP-
Puro cells showed a significant interaction among the selected factors. For lipoplex 
formulations, significant statistical differences were observed among groups. 
siRNA+pDNA, siRNA+PG1 and siRNA+PG2 lipoplexes induced a higher percentage of 
EGFP silencing than siRNA lipoplexes (F(5,168)=13.815, P<0.05). No significant 
differences were observed between C.R. (+/-) and siRNA concentrations. 
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Figure 20 - EGFP silencing on 293T/GFP-Puro cell line, incubated with the different lipoplex formulations, for 48 h. 
Different letters indicate significant differences among treatments (P<0.05, nested design ANOVA). Untreated cells 
(cells), siRNA lipoplexes (SI), siRNA+pDNA lipoplexes (SI+D), siRNA+PG1 lipoplexes (SI+PG1), siRNA+PG2 (SI+PG2) 
and lipofectamine (LIPO). 
 
 The results on Fig. 20 show that siRNA lipoplexes did not promote a significant 
decrease in fluorescence intensity when compared to the non-treated cells. However, 
when pDNA, PG1 and PG2 were included in the lipoplex formulation, it was possible to 
observe a significant decrease in fluorescence intensity, even though the same amount 
of siRNA was used for each formulation. This suggests that less siRNA is needed to 
achieve EGFP silencing when pDNA or PG molecules are added to the formulation. One 
possible explanation is that the addition of the anionic cargo may lead to the 
formation of different lipoplex structures when compared to lipoplexes encapsulating 
siRNA alone. Addition of anionic cargo may result in less stable lipoplexes, which will 
facilitate endosomal escape and cargo release, resulting in higher siRNA delivery, and 
thus promoting higher levels of gene silencing for the same siRNA concentration. Also, 
the presence of pDNA or PG molecules could help the dissociation of the lipoplexes by 
interaction/competition with cell surface proteoglycans [16]. Since internalization 
efficiency studies showed that very little number of siRNA was successfully internalized 
by cells, it is also possible to observe that a small amount of siRNA is needed inside the 
cell to promote significant reduction in gene expression. 
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5.2 qPCR 
 Lipoplex ability to silence EGFR expression was tested in MDA-MB-468 cells. To 
avoid the significant toxicity observed in previous experiments with C.R. (+/-) 10, 
lipoplexes were prepared at C.R. (+/-) 5, at a final siRNA concentration of 50 nM per 
well. Two independent experiments were performed for the PCR assay.  
 
Figure 21 - EGFR silencing on MDA-MB-468 cell line as determined by qPCR, after treatment with the different 
lipoplexes prepared at charge ratio (+/-) 5 and final siRNA concentration of 50 nM for 24 h.  
 The results observed in Fig. 21 show that cells treated with lipofectamine 
presented the highest levels of EGFR gene silencing. siRNA+PG1 lipoplexes also 
promoted significant reduction in EGFR expression, while siRNA, siRNA+pDNA and 
siRNA+PG2 lipoplexes promoted overexpression of the gene. This overexpression 
might be associated with the formation of primer dimers (PD), leading to competition 
for PCR reagents, which may interfere with accurate gene expression quantification. 
Another hypothesis is that maybe GADPH was not the most suitable endogenous gene 
for this experiment. Studies have reported that GADPH is not the most adequate gene 
to quantify cellular normal expression due to its relatively large expression error [90]. 
This experiment was just a preliminary test, since only one time-point was analyzed. 
Besides, only two individual PCR experiments were performed without replicas, 
therefore, results with high standard deviation are unreliable. Additional experiments, 
with a different reference gene, should be performed in order to better evaluate the 
silencing efficiency of the systems. Also, protein expression studies such as western-
blot assays would help to further understand the silencing efficiency of these systems. 
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Nevertheless, results for siRNA+PG1 lipoplexes show some level of EGFR gene silencing 
for both experiments performed, which can be a good indication of the silencing 
potential of these systems. 
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IV - Conclusion and future work 
 In this work, liposomes obtained by sonication, ethanol injection and extrusion 
were analyzed by DLS. We were able the see that different methods of liposome 
preparation result in liposomes with distinct characteristics. Liposomes prepared by 
sonication can be tuned to present suitable sizes for siRNA delivery, however, the 
liposome suspensions obtained were very unstable. As for ethanol injection and 
extrusion, even though both methods resulted in liposomes with approximately the 
same relatively small hydrodynamic diameter (≈ 16  nm),   I value  o  l po ome  
obtained by extrusion were lower. From ELS measurements we have understood that 
extrusion promotes liposomes with more positively charged surface (≈ 6  mV) when 
compa ed to l po ome  obta ned by ethanol  nject on (≈    mV). Even thou h 
extrusion is a more reproducible method, the time consumed in the process and the 
retention of lipid in the membranes are important disadvantages for these technique. 
These studies led us to conclude that ethanol injection was the more suitable 
preparation method for our purposes. 
 DLS measurements of siRNA, siRNA+pDNA, siRNA+PG1 and siRNA+PG2 
lipoplexes, showed that the addition of pDNA, PG1 and PG2 promote the compaction 
of siRNA at lower C.R. (+/-). However, at C.R. (+/-) > 4, all lipoplex formulations present 
a   m la  mean d amete  (≈1   nm) and ζ-potential (≈+   mV), suggesting that the 
addition of an anionic cargo does not significantly affect the final siRNA complexation 
efficiency, with the different lipoplexes progressing towards structures with similar 
mean   ze  and ζ-potential. In what encapsulation efficiency was concerned, lipoplexes 
prepared with PG1 or PG2 seem to promote a slight increase in siRNA encapsulation 
for lower C.R. (+/-). As discussed before, the same behavior was not observed for 
siRNA+pDNA lipoplexes possibly due to the unspecific binding of RiboGreen to pDNA 
molecules. Therefore, no distinctions can be made between the different anionic 
cargos, as for C.R. (+/-) >   all l pople e  p e ent h  h encap ulat on e   c ency (≈9  %). 
These results are in accordance with DLS measurements, a fact that further attests  
that the presence of the different anionic components did not had a significant 
outcome in the siRNA encapsulation/complexation process. 
 Concerning lipoplexes cellular uptake, fluorescence measurements have shown 
poor internalization for all  y tem   n both  93T (≈  %) and    -MD-46  (≈3 %) cell 
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lines. However, fluorescence microscopy analysis seems to suggest a more efficient 
cellular uptake, mainly in systems where siRNA was co-encapsulated with PG and 
pDNA. 
 Metabolic activity of 293T cells after administration of the lipoplex compounds 
individually showed that, for the tested concentrations (25 and 50 nM of siRNA), the 
only compound that significantly reduced metabolic activity were the liposomes used 
to co-encapsulate siRNA with either pDNA or PG. This reduction in metabolic activity is 
similar to the effects obtained with all lipoplex formulations. Interestingly, lipoplexes 
co-encapsulating siRNA and pDNA or PG presented the same cytotoxicity levels as 
siRNA lipoplexes, even though these systems were prepared with twice the amount of 
lipid.  The same tendency was observed for the MDA-MB-468 cell line, reinforcing the 
idea that addition of anionic cargo does not enhance the cytotoxicity of the systems. 
 Finally, regarding gene silencing efficiency, the fluorescence microscopy assay 
has shown that no significant differences were observed between different lipoplex 
C.R. (+/-) or concentrations. More importantly, lipoplexes with pDNA, PG1 and PG2, 
clearly show an enhanced silencing efficiency of EGFP expression when compared to 
siRNA lipoplexes. The qPCR assay showed that siRNA lipoplexes prepared with PG1 
might be a promising system to promote knockdown of EGFR expression. However, as 
discussed before, the results obtained are preliminary, since more experiments should 
be performed at different time points and using a more suitable reporter gene. 
 In sum, the different lipoplexes prepared in this work were highly efficient in 
the encapsulation of siRNA, did not promote a significant cytotoxicity to 293T and 
MDA-MB-468 cells, and showed promising results in gene silencing. Moreover, the co-
encapsulation with the anionic compounds show some improvements on the 
siRNA/DODAB/MO base system. 
Several studies can be developed in the future in order to better understand 
the influence of an anionic cargo in siRNA lipoplexes. Methods such as calorimetry or 
cryo-TEM should be performed in order to understand the lipoplexes structural 
differences. The stability in physiologic fluids, such as serum, and membrane fusion 
assays might also be valuable methods to infer if the additional anionic components 
can enhance the system's ability to deliver siRNA. As referred before, flow cytometry, 
and confocal microscopy would allow for better assessment of the systems 
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internalization in cells. Additional qPCR and western-blot assays should be performed 
at different time-points to conclusively report the gene silencing ability of the systems. 
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